{
  "usdmVersion": "4.0",
  "generatedAt": "2025-12-30T01:42:54.266940",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "e1077a57-5a58-492c-a98d-33f374b153c1",
    "instanceType": "Study",
    "versions": [
      {
        "id": "e1c33d9a-5adf-4ff8-bc69-fdf294bbfaf3",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "86c0b2d6-478b-44b4-bd78-cfdf4b6f7d69",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "361d1d7d-741d-4362-a9cf-c868adaafbb2",
              "standardCode": {
                "id": "0ded781e-86ea-48af-88e1-1eeafc37a868",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "c0d4dcd7-f941-4f25-9031-1cf3424e8b88",
                "name": "LY900018",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Single 3-mg dose of nasal glucagon (LY900018) administered by study site personnel.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "6fc30e70-926f-45bf-9c31-09274bbd2cdc",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "caf70993-2c38-4d93-a080-c3131b222edf",
                "name": "Intramuscular Glucagon (IMG)",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Single 1-mg dose of intramuscular glucagon (IMG, GlucaGen) administered by study site personnel.",
                "type": {
                  "id": "C174267",
                  "code": "C174267",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Active Comparator Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "64049bae-4856-40e0-a757-ccafc8f8caaf",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "60aee775-8ca6-4f2c-a819-18893e870cb6",
                "name": "Type 1 Diabetes Mellitus (T1DM)",
                "instanceType": "StudyCohort",
                "characteristic": "Patients with a diagnosis of T1DM on daily insulin therapy for at least 1 year."
              },
              {
                "id": "07033b99-ea1a-4641-ac2f-27632c366667",
                "name": "Type 2 Diabetes Mellitus (T2DM)",
                "instanceType": "StudyCohort",
                "characteristic": "Patients with a diagnosis of T2DM on daily insulin therapy for at least 1 year."
              }
            ],
            "studyCells": [
              {
                "id": "2ecadf18-08cc-46e5-83fa-e7eec25aeb97",
                "armId": "c0d4dcd7-f941-4f25-9031-1cf3424e8b88",
                "epochId": "994d6a34-4a13-488b-a4cf-40ecc6bda61f",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "e0b49310-a097-45ad-a24d-ff55a1a16f53",
                "armId": "c0d4dcd7-f941-4f25-9031-1cf3424e8b88",
                "epochId": "fae0d8e6-e487-4435-b3d0-fbf6e0965f1f",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "2e328d1f-62a1-4650-8d62-70a789e27f8d",
                "armId": "c0d4dcd7-f941-4f25-9031-1cf3424e8b88",
                "epochId": "1ed1434e-0ed2-4c1b-8712-457199602601",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "204c9001-7e14-485d-93da-816bc998bfd1",
                "armId": "caf70993-2c38-4d93-a080-c3131b222edf",
                "epochId": "994d6a34-4a13-488b-a4cf-40ecc6bda61f",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "2b1df101-bf80-49c1-af5f-c74ce9c20690",
                "armId": "caf70993-2c38-4d93-a080-c3131b222edf",
                "epochId": "fae0d8e6-e487-4435-b3d0-fbf6e0965f1f",
                "elementIds": [],
                "instanceType": "StudyCell"
              },
              {
                "id": "6fc7b865-2ef6-401f-b29c-0d4f1bf68759",
                "armId": "caf70993-2c38-4d93-a080-c3131b222edf",
                "epochId": "1ed1434e-0ed2-4c1b-8712-457199602601",
                "elementIds": [],
                "instanceType": "StudyCell"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "4d27acfc-a120-4e55-9ea5-a8c0ca38734d",
                "identifier": "[1]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a6c71142-2ca3-4357-99f9-814f86cfea84",
                "instanceType": "EligibilityCriterion",
                "name": "Diagnosis of T1DM or T2DM",
                "nextId": "edf24bbf-4bc0-4ef0-87b7-702bb10c82fc"
              },
              {
                "id": "edf24bbf-4bc0-4ef0-87b7-702bb10c82fc",
                "identifier": "[2]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "060ea57b-271a-4206-94bb-753af9f774a6",
                "instanceType": "EligibilityCriterion",
                "name": "Contraception for male patients",
                "previousId": "4d27acfc-a120-4e55-9ea5-a8c0ca38734d",
                "nextId": "a7e19bca-24ed-4bab-b0ea-3405cd675c38"
              },
              {
                "id": "a7e19bca-24ed-4bab-b0ea-3405cd675c38",
                "identifier": "[3]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "30c403f9-5e04-4d93-abd6-241915b6640f",
                "instanceType": "EligibilityCriterion",
                "name": "Requirements for female patients",
                "previousId": "edf24bbf-4bc0-4ef0-87b7-702bb10c82fc",
                "nextId": "8037a5f8-3a72-4ad0-a172-49287102d32a"
              },
              {
                "id": "8037a5f8-3a72-4ad0-a172-49287102d32a",
                "identifier": "[4]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "d0c10480-34bc-4eb2-9de3-ee3d48d23f96",
                "instanceType": "EligibilityCriterion",
                "name": "Age requirements",
                "previousId": "a7e19bca-24ed-4bab-b0ea-3405cd675c38",
                "nextId": "811336cb-3361-45f3-83c4-3c6cd94922e5"
              },
              {
                "id": "811336cb-3361-45f3-83c4-3c6cd94922e5",
                "identifier": "[5]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4d6351a2-5a3c-42de-b888-c666b5ad8650",
                "instanceType": "EligibilityCriterion",
                "name": "Body mass index requirements",
                "previousId": "8037a5f8-3a72-4ad0-a172-49287102d32a",
                "nextId": "4ba163f7-3c5c-43ed-84f7-16fdffec688a"
              },
              {
                "id": "4ba163f7-3c5c-43ed-84f7-16fdffec688a",
                "identifier": "[6]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9094b11b-93d8-44aa-9923-0479701d9e28",
                "instanceType": "EligibilityCriterion",
                "name": "Hemoglobin A1c value",
                "previousId": "811336cb-3361-45f3-83c4-3c6cd94922e5",
                "nextId": "5ae5c09e-1674-4f92-b87a-208ff2ce1f0b"
              },
              {
                "id": "5ae5c09e-1674-4f92-b87a-208ff2ce1f0b",
                "identifier": "[7]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8b01612e-7c93-49f0-961e-ddb78250926b",
                "instanceType": "EligibilityCriterion",
                "name": "Clinical laboratory test results",
                "previousId": "4ba163f7-3c5c-43ed-84f7-16fdffec688a",
                "nextId": "dacc52a0-1ed3-4938-bdf8-d970b9da871e"
              },
              {
                "id": "dacc52a0-1ed3-4938-bdf8-d970b9da871e",
                "identifier": "[8]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b7a7ecda-35dd-4089-90ed-f36bc2f9d017",
                "instanceType": "EligibilityCriterion",
                "name": "Venous access",
                "previousId": "5ae5c09e-1674-4f92-b87a-208ff2ce1f0b",
                "nextId": "b0515b1c-ff00-40f3-b441-c20de28d3db5"
              },
              {
                "id": "b0515b1c-ff00-40f3-b441-c20de28d3db5",
                "identifier": "[9]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8c3e9868-e127-46b7-9bc4-c65085a72f01",
                "instanceType": "EligibilityCriterion",
                "name": "Willingness to participate",
                "previousId": "dacc52a0-1ed3-4938-bdf8-d970b9da871e",
                "nextId": "39a1d976-962b-4de9-8353-a3bb6e702259"
              },
              {
                "id": "39a1d976-962b-4de9-8353-a3bb6e702259",
                "identifier": "[10]",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2e4ddc4a-e85c-436d-9f48-678769916911",
                "instanceType": "EligibilityCriterion",
                "name": "Informed consent",
                "previousId": "b0515b1c-ff00-40f3-b441-c20de28d3db5"
              },
              {
                "id": "266babd6-6213-46f5-bdc5-9c2595a932f1",
                "identifier": "[11]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a4fec6bf-3bdc-401d-83f5-a8ca54e185b0",
                "instanceType": "EligibilityCriterion",
                "name": "Investigative site personnel affiliation",
                "nextId": "810714c7-d87c-4c77-b324-7696a56f1a76"
              },
              {
                "id": "810714c7-d87c-4c77-b324-7696a56f1a76",
                "identifier": "[12]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9acf6cb9-a2fa-4cd9-898d-860df1cfac94",
                "instanceType": "EligibilityCriterion",
                "name": "Lilly employees",
                "previousId": "266babd6-6213-46f5-bdc5-9c2595a932f1",
                "nextId": "6862f099-711e-471f-a561-295174f1d85d"
              },
              {
                "id": "6862f099-711e-471f-a561-295174f1d85d",
                "identifier": "[13]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c2a04ff3-8bc8-4405-b2fe-d4949f81fc9f",
                "instanceType": "EligibilityCriterion",
                "name": "Current enrollment in other clinical trials",
                "previousId": "810714c7-d87c-4c77-b324-7696a56f1a76",
                "nextId": "69a27e72-a5f8-4ab3-8fab-606d8143c656"
              },
              {
                "id": "69a27e72-a5f8-4ab3-8fab-606d8143c656",
                "identifier": "[14]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c541b32a-72e9-4b3e-a12b-cc01a032d4c2",
                "instanceType": "EligibilityCriterion",
                "name": "Recent participation in other clinical trials",
                "previousId": "6862f099-711e-471f-a561-295174f1d85d",
                "nextId": "ac76f644-8446-463b-9ca2-efbb18772e14"
              },
              {
                "id": "ac76f644-8446-463b-9ca2-efbb18772e14",
                "identifier": "[15]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1b9094d2-e0a3-418e-91f1-65866061e80d",
                "instanceType": "EligibilityCriterion",
                "name": "Previous participation in this or other LY900018 studies",
                "previousId": "69a27e72-a5f8-4ab3-8fab-606d8143c656",
                "nextId": "2b3911e1-9f8b-47ab-a956-aaf4c2b6303e"
              },
              {
                "id": "2b3911e1-9f8b-47ab-a956-aaf4c2b6303e",
                "identifier": "[16]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8d9a9e1b-5917-4d35-ba89-d6e5305f08a8",
                "instanceType": "EligibilityCriterion",
                "name": "Known allergies or sensitivity",
                "previousId": "ac76f644-8446-463b-9ca2-efbb18772e14",
                "nextId": "68f7b9ce-f5e0-47b0-a5ed-c81894993b78"
              },
              {
                "id": "68f7b9ce-f5e0-47b0-a5ed-c81894993b78",
                "identifier": "[17]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "13199f5b-ca6b-4b39-afdf-0626cef129ec",
                "instanceType": "EligibilityCriterion",
                "name": "Abnormality in 12-lead ECG",
                "previousId": "2b3911e1-9f8b-47ab-a956-aaf4c2b6303e",
                "nextId": "910d1ce8-4291-4864-a64d-06d3be63562c"
              },
              {
                "id": "910d1ce8-4291-4864-a64d-06d3be63562c",
                "identifier": "[18]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "653fe0d4-ba5e-43a2-8d9f-1fc8a808904f",
                "instanceType": "EligibilityCriterion",
                "name": "Significant changes in insulin regimen",
                "previousId": "68f7b9ce-f5e0-47b0-a5ed-c81894993b78",
                "nextId": "d5e3f5c8-ef66-490a-8b72-715ab684adee"
              },
              {
                "id": "d5e3f5c8-ef66-490a-8b72-715ab684adee",
                "identifier": "[19]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "e93a808e-1f10-49a7-b41c-c62bcbe561c6",
                "instanceType": "EligibilityCriterion",
                "name": "High total daily dose of insulin",
                "previousId": "910d1ce8-4291-4864-a64d-06d3be63562c",
                "nextId": "00ced712-6f32-4e04-9c59-8b07b99a187b"
              },
              {
                "id": "00ced712-6f32-4e04-9c59-8b07b99a187b",
                "identifier": "[20]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "5631f0a3-18d3-45eb-a850-249a74039c90",
                "instanceType": "EligibilityCriterion",
                "name": "Poorly controlled hypertension",
                "previousId": "d5e3f5c8-ef66-490a-8b72-715ab684adee",
                "nextId": "570ec7eb-e9a5-4a36-8fa6-db8355e136d0"
              },
              {
                "id": "570ec7eb-e9a5-4a36-8fa6-db8355e136d0",
                "identifier": "[21]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "489545cc-47cb-49b1-8db0-b4414ae8b893",
                "instanceType": "EligibilityCriterion",
                "name": "History of pheochromocytoma or insulinoma",
                "previousId": "00ced712-6f32-4e04-9c59-8b07b99a187b",
                "nextId": "d99c11db-10b8-449d-9a7f-726e926d4c7c"
              },
              {
                "id": "d99c11db-10b8-449d-9a7f-726e926d4c7c",
                "identifier": "[22]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "14941e33-5706-4c37-9e11-921e148258fb",
                "instanceType": "EligibilityCriterion",
                "name": "History of severe hypoglycemia or loss of consciousness",
                "previousId": "570ec7eb-e9a5-4a36-8fa6-db8355e136d0",
                "nextId": "35497065-714a-4dd3-835e-84ce51dd5db3"
              },
              {
                "id": "35497065-714a-4dd3-835e-84ce51dd5db3",
                "identifier": "[23]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3d9b1c61-56d8-49bb-b1ba-0597ccb5a70b",
                "instanceType": "EligibilityCriterion",
                "name": "History of epilepsy or seizure disorder",
                "previousId": "d99c11db-10b8-449d-9a7f-726e926d4c7c",
                "nextId": "90cf893d-a24a-4531-a292-6ebcf9f2a9da"
              },
              {
                "id": "90cf893d-a24a-4531-a292-6ebcf9f2a9da",
                "identifier": "[24]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4dc1e374-05a7-462f-8ae5-7bf0893d23ad",
                "instanceType": "EligibilityCriterion",
                "name": "History of significant disorders",
                "previousId": "35497065-714a-4dd3-835e-84ce51dd5db3",
                "nextId": "e703ce26-3416-4477-8e3e-9099e413711f"
              },
              {
                "id": "e703ce26-3416-4477-8e3e-9099e413711f",
                "identifier": "[25]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8dd8afe4-41f9-4fc5-9f39-f69be4932139",
                "instanceType": "EligibilityCriterion",
                "name": "Known or ongoing psychiatric disorders",
                "previousId": "90cf893d-a24a-4531-a292-6ebcf9f2a9da",
                "nextId": "a3962b77-46d2-4151-bea7-8ab364c47add"
              },
              {
                "id": "a3962b77-46d2-4151-bea7-8ab364c47add",
                "identifier": "[26]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "515607c6-f1f5-4911-ac44-08d976c6259b",
                "instanceType": "EligibilityCriterion",
                "name": "Use of drugs of abuse",
                "previousId": "e703ce26-3416-4477-8e3e-9099e413711f",
                "nextId": "fc505d98-d741-4f57-b20b-93ceb65fa124"
              },
              {
                "id": "fc505d98-d741-4f57-b20b-93ceb65fa124",
                "identifier": "[27]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9ffc5389-77de-43d6-8f47-495a64de55b7",
                "instanceType": "EligibilityCriterion",
                "name": "Evidence of HIV infection",
                "previousId": "a3962b77-46d2-4151-bea7-8ab364c47add",
                "nextId": "ff6e3551-ba32-40f7-afa8-c69bce7a9f37"
              },
              {
                "id": "ff6e3551-ba32-40f7-afa8-c69bce7a9f37",
                "identifier": "[28]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9539f3e1-24fe-40b0-b416-38db559b74cc",
                "instanceType": "EligibilityCriterion",
                "name": "Evidence of hepatitis C",
                "previousId": "fc505d98-d741-4f57-b20b-93ceb65fa124",
                "nextId": "de2d8f39-8bcf-4215-8a3b-f59b1f015377"
              },
              {
                "id": "de2d8f39-8bcf-4215-8a3b-f59b1f015377",
                "identifier": "[29]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c6b15524-299f-4be2-802a-dfff09d11f84",
                "instanceType": "EligibilityCriterion",
                "name": "Evidence of hepatitis B",
                "previousId": "ff6e3551-ba32-40f7-afa8-c69bce7a9f37",
                "nextId": "e49f9d7b-d3aa-4fc7-b40c-91673bb6612a"
              },
              {
                "id": "e49f9d7b-d3aa-4fc7-b40c-91673bb6612a",
                "identifier": "[30]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a5311bcd-c44f-4b63-9819-7f8a6ce64519",
                "instanceType": "EligibilityCriterion",
                "name": "Evidence of syphilis",
                "previousId": "de2d8f39-8bcf-4215-8a3b-f59b1f015377",
                "nextId": "3fba8b33-6c38-407b-8218-b2da5b98cc6e"
              },
              {
                "id": "3fba8b33-6c38-407b-8218-b2da5b98cc6e",
                "identifier": "[31]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "5d94d3ec-e208-4373-b80c-ea00a0b3eeab",
                "instanceType": "EligibilityCriterion",
                "name": "Lactating women",
                "previousId": "e49f9d7b-d3aa-4fc7-b40c-91673bb6612a",
                "nextId": "a1ff8b82-7d16-4277-9fd0-6d6789f52208"
              },
              {
                "id": "a1ff8b82-7d16-4277-9fd0-6d6789f52208",
                "identifier": "[32]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "674ffccf-ff2b-4105-9fc8-953699e8caf2",
                "instanceType": "EligibilityCriterion",
                "name": "Use of specific medications",
                "previousId": "3fba8b33-6c38-407b-8218-b2da5b98cc6e",
                "nextId": "bc7c00fc-3266-40ee-902e-7c349d563baf"
              },
              {
                "id": "bc7c00fc-3266-40ee-902e-7c349d563baf",
                "identifier": "[33]",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9bba8753-244e-414f-a99c-0bd47783840c",
                "instanceType": "EligibilityCriterion",
                "name": "Recent blood donation",
                "previousId": "a1ff8b82-7d16-4277-9fd0-6d6789f52208"
              }
            ],
            "population": {
              "id": "47ad7d66-b2d6-4637-bf1e-4af1a1c7dba9",
              "instanceType": "StudyDesignPopulation",
              "name": "Study Population",
              "description": "Target population for the study as defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "11cfa7ba-05a9-40b7-bfec-61c6ed562ece",
                "name": "Primary Objective",
                "text": "To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "7047ff9d-da37-44bf-aac6-76b28d683471"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "36482230-3066-403c-a5bf-6430e1c22df9",
                "name": "Secondary Safety and Tolerability Objective",
                "text": "To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "04a69c66-9c47-4283-8236-9d35cd6cafdc"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "d1199583-1400-4fa6-b9b1-eba5388c0c84",
                "name": "Secondary PK Objective",
                "text": "To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "1b25113f-eb1a-4cc2-b243-20884ee83161"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "d2a606e2-912b-4a40-b71e-a99b0995ba05",
                "name": "Secondary PD Objective",
                "text": "To characterize the PD profile of 3 mg LY900018 compared to 1 mg IMG",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "bb4d343b-37fe-4ccf-b336-10d81ca57007"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "7047ff9d-da37-44bf-aac6-76b28d683471",
                "name": "Primary Efficacy Endpoint",
                "text": "The proportion of patients achieving treatment success defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir within 30 minutes after administration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration.",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "04a69c66-9c47-4283-8236-9d35cd6cafdc",
                "name": "Safety and Tolerability Endpoints",
                "text": "SAE, TEAEs (including gastrointestinal, nasal, and non-nasal AEs), vital signs",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "1b25113f-eb1a-4cc2-b243-20884ee83161",
                "name": "PK Endpoint",
                "text": "PK parameters include AUC, Cmax, Tmax",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacokinetic"
              },
              {
                "id": "bb4d343b-37fe-4ccf-b336-10d81ca57007",
                "name": "PD Endpoint",
                "text": "PD parameters include BGmax and Tmax",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Pharmacodynamic"
              }
            ],
            "studyInterventions": [
              {
                "id": "dff61a57-4bf5-4ea2-ae80-be060f85b0f9",
                "name": "LY900018",
                "role": {
                  "id": "2a506003-89bc-4b7f-821f-4ed4f741916c",
                  "code": "Investigational Product",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Investigational Product",
                  "instanceType": "Code"
                },
                "instanceType": "StudyIntervention",
                "description": "Nasal glucagon (LY900018) is a powder formulation of human glucagon for the rescue treatment of hypoglycemia.",
                "productIds": [
                  "d4f3e666-9769-46c1-8b28-07ed6d51ec14"
                ],
                "administrationIds": [
                  "9b37ef59-85b1-4cac-980a-35643aad670b"
                ]
              },
              {
                "id": "ed7c89db-14c0-4a2b-bffa-c126d14be005",
                "name": "GlucaGen",
                "role": {
                  "id": "3f84eaf7-ad22-4d15-bc5f-98b6f2d4e20d",
                  "code": "Comparator",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Comparator",
                  "instanceType": "Code"
                },
                "instanceType": "StudyIntervention",
                "description": "Intramuscular glucagon (IMG) used as an active comparator.",
                "productIds": [
                  "ab642a9a-c0c6-4642-ac4c-ee2932d72d82"
                ],
                "administrationIds": [
                  "e5c2b661-bdab-44c2-9e40-6bb21be8aa29"
                ]
              },
              {
                "id": "7e9bb1dd-e064-4b9b-bd26-460f62542f1c",
                "name": "Human regular insulin",
                "role": {
                  "id": "dfe3efde-379e-4fe9-995b-63704f5efdcf",
                  "code": "Concomitant Medication",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Concomitant Medication",
                  "instanceType": "Code"
                },
                "instanceType": "StudyIntervention",
                "description": "Administered via IV infusion to induce hypoglycemia for the study procedure.",
                "productIds": [
                  "5997c1b9-1196-4a46-bbe8-b36d10494845"
                ],
                "administrationIds": [
                  "9d22cd5a-3ef0-4989-8ed1-d52312872a68"
                ]
              },
              {
                "id": "6717cc3b-8b70-4177-afd5-7aadd9bc020e",
                "name": "IV glucose",
                "role": {
                  "id": "46049bb2-21b5-42e6-b76d-3db0de330fb5",
                  "code": "Rescue Medication",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Rescue Medication",
                  "instanceType": "Code"
                },
                "instanceType": "StudyIntervention",
                "description": "Administered if a patient's bedside plasma glucose concentration remains low after glucagon administration or if severe hypoglycemia symptoms occur.",
                "productIds": [
                  "c7f38baf-1e35-41f3-9aef-8628f6988cc0"
                ],
                "administrationIds": [
                  "6f3e6cb6-7945-410c-b2da-8a9103977e00"
                ]
              }
            ],
            "scheduleTimelines": [
              {
                "id": "9a611228-a50d-44aa-85c6-f6500a41daae",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "ce3e1be2-c1ec-4852-b3ff-3ca4ac3891b0",
                "instances": [
                  {
                    "id": "ce3e1be2-c1ec-4852-b3ff-3ca4ac3891b0",
                    "activityIds": [
                      "982149fc-8c0a-474e-b733-76cffae5fe4b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "9ced3417-94b2-4b8a-8daf-708bb33f5618",
                    "activityIds": [
                      "d060dd8d-1d07-44b1-87fa-95952282a885"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "bd904301-5037-4c96-bdf4-9ee8c02e33f6",
                    "activityIds": [
                      "ea0b3c03-0fc8-48c1-87ed-accc19e67c61"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_2",
                    "encounterId": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3"
                  },
                  {
                    "id": "d1589d4f-c6d3-4b28-843b-ed3be07edb49",
                    "activityIds": [
                      "ea0b3c03-0fc8-48c1-87ed-accc19e67c61"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_5",
                    "encounterId": "192c5a1b-9297-4a63-9e18-2df52dc4d3a4"
                  },
                  {
                    "id": "a682c076-b959-4bc7-bb81-8fdd4ea606c1",
                    "activityIds": [
                      "276e4f65-6e06-4f80-876b-f1f3b0070fc6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "4414f410-53d7-4a91-95b3-ec6bc10f20f0",
                    "activityIds": [
                      "276e4f65-6e06-4f80-876b-f1f3b0070fc6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "d5d78c73-64b8-4914-81e0-49b18904f66b",
                    "activityIds": [
                      "5b23d146-5158-4a9b-8da0-6fb3f1b00ca2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "e65aeccb-5b1d-4cab-9246-7f697cf59227",
                    "activityIds": [
                      "d5b31513-9642-4aae-a4d5-d4a74f87718d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "f0d05604-9362-4224-bf2f-8790157733c2",
                    "activityIds": [
                      "d5b31513-9642-4aae-a4d5-d4a74f87718d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_2",
                    "encounterId": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3"
                  },
                  {
                    "id": "79eb4f31-6d22-47d9-9e9c-891e5e3c90b6",
                    "activityIds": [
                      "d5b31513-9642-4aae-a4d5-d4a74f87718d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "ce0104d1-2202-44f9-bb2b-e44deccfb5c9",
                    "activityIds": [
                      "d5b31513-9642-4aae-a4d5-d4a74f87718d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_4",
                    "encounterId": "0e9532a0-a494-46ed-b80d-9753cbe4afb1"
                  },
                  {
                    "id": "0f624198-ec7c-4822-b9ae-9215b5a9a7a1",
                    "activityIds": [
                      "d5b31513-9642-4aae-a4d5-d4a74f87718d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_5",
                    "encounterId": "192c5a1b-9297-4a63-9e18-2df52dc4d3a4"
                  },
                  {
                    "id": "0dcb73c1-532f-47eb-a73e-f660af581b0d",
                    "activityIds": [
                      "d5b31513-9642-4aae-a4d5-d4a74f87718d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "bd81349a-5c1f-42cb-beae-1caecc06d89a",
                    "activityIds": [
                      "d5b31513-9642-4aae-a4d5-d4a74f87718d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "48e60e63-85f8-44cd-bdc6-ab03c4e71b2c",
                    "activityIds": [
                      "64d68d45-2a38-4ae7-9012-7aabcf9f5c2f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "d40e7e8e-f103-460d-acf4-62ea1c1dbe32",
                    "activityIds": [
                      "64d68d45-2a38-4ae7-9012-7aabcf9f5c2f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "4caf6b98-87ae-4637-aa96-7131e49bbc38",
                    "activityIds": [
                      "64d68d45-2a38-4ae7-9012-7aabcf9f5c2f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "5e651349-f9a9-4d10-abbf-2e382f32f89c",
                    "activityIds": [
                      "64d68d45-2a38-4ae7-9012-7aabcf9f5c2f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "997e7def-3f02-417f-a1da-b60ea84c1d93",
                    "activityIds": [
                      "c616b64d-abe1-4472-b41f-d79db7bd61e4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "c1e887dc-2a16-45d6-b027-f887d4fde8de",
                    "activityIds": [
                      "c616b64d-abe1-4472-b41f-d79db7bd61e4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "cbf0ee66-76fb-4a92-b9d4-a435a697ca79",
                    "activityIds": [
                      "c616b64d-abe1-4472-b41f-d79db7bd61e4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "6dbba68d-4921-4791-a6cc-1d59cf88bb31",
                    "activityIds": [
                      "c616b64d-abe1-4472-b41f-d79db7bd61e4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "ad1f4eca-59f6-46c2-a8d3-92ec2d1a836f",
                    "activityIds": [
                      "00001555-e6d7-47d4-a7f4-b6c00eecdf50"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "bb776723-0215-40c6-bb0b-f380effa7ec0",
                    "activityIds": [
                      "00001555-e6d7-47d4-a7f4-b6c00eecdf50"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "c2b32753-89d6-49b1-bafe-8f5ccff6df64",
                    "activityIds": [
                      "90898c34-49e3-4479-be83-ba1a94f8b915"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "2c57e9af-9fb7-4358-b902-5bf1503dbf0f",
                    "activityIds": [
                      "90898c34-49e3-4479-be83-ba1a94f8b915"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_2",
                    "encounterId": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3"
                  },
                  {
                    "id": "83978e99-a5f3-49f9-b412-87ea7cded698",
                    "activityIds": [
                      "90898c34-49e3-4479-be83-ba1a94f8b915"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "1eba86e4-0407-4eb6-a98a-02aea9cab380",
                    "activityIds": [
                      "90898c34-49e3-4479-be83-ba1a94f8b915"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_4",
                    "encounterId": "0e9532a0-a494-46ed-b80d-9753cbe4afb1"
                  },
                  {
                    "id": "04bd348d-137b-4b0f-ac7e-a9210ea4991e",
                    "activityIds": [
                      "90898c34-49e3-4479-be83-ba1a94f8b915"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_5",
                    "encounterId": "192c5a1b-9297-4a63-9e18-2df52dc4d3a4"
                  },
                  {
                    "id": "2fd87f27-529a-43e9-84bc-6d0be2cab0dc",
                    "activityIds": [
                      "90898c34-49e3-4479-be83-ba1a94f8b915"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "0a0a812b-c32b-4842-b1da-912b97857c90",
                    "activityIds": [
                      "90898c34-49e3-4479-be83-ba1a94f8b915"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "a760e5c3-8384-4116-8a09-5837e7775fe3",
                    "activityIds": [
                      "997da135-d078-44a3-8b08-57cc6d056f2a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "90531550-74e4-481a-8de9-37d6a3febcf6",
                    "activityIds": [
                      "997da135-d078-44a3-8b08-57cc6d056f2a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "9465f94d-66c9-4b4c-8a35-c91d9d8ec1ae",
                    "activityIds": [
                      "0128a51d-c4d3-4a46-9eea-8556f0a958c2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "30ff2a40-2333-4652-a516-583597a7f374",
                    "activityIds": [
                      "0128a51d-c4d3-4a46-9eea-8556f0a958c2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "24400ee3-fca5-4311-b9f0-4df8e45f944d",
                    "activityIds": [
                      "18d50b7a-c5f1-4efe-8ca8-cf92985c7980"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "4b1a0501-0c67-4596-87a9-4fcaafcd656b",
                    "activityIds": [
                      "18d50b7a-c5f1-4efe-8ca8-cf92985c7980"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "b6d5241a-9c3c-47fe-812f-14db337199e1",
                    "activityIds": [
                      "1757c44f-8cb5-45e6-bde1-5011f27eaf7f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "a13f779f-0e1d-4c6e-a22e-42495795af99",
                    "activityIds": [
                      "1757c44f-8cb5-45e6-bde1-5011f27eaf7f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "536d19b2-8170-4d20-9beb-702d96a76766",
                    "activityIds": [
                      "b6ccc49d-46ef-43b1-86f7-41950a4433cc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "ee3fb18b-db3d-4004-9158-373d69678e54",
                    "activityIds": [
                      "b6ccc49d-46ef-43b1-86f7-41950a4433cc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "321a5041-f26f-430e-8af9-3cc6ef0862a8",
                    "activityIds": [
                      "32e71b97-f083-41e6-a4b6-ea523dd73677"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "0f67240a-811a-4fd3-8152-f2efe1fbde0e",
                    "activityIds": [
                      "32e71b97-f083-41e6-a4b6-ea523dd73677"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "d1a20ff9-7bc6-44d0-9054-e033a772e038",
                    "activityIds": [
                      "1febba99-cf83-4f48-9101-37050b74abd3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "502f4a7a-82bd-4567-991d-a2f9e3c4c762",
                    "activityIds": [
                      "1febba99-cf83-4f48-9101-37050b74abd3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "9d714cdb-a8e9-483e-8792-3c7688614276",
                    "activityIds": [
                      "1febba99-cf83-4f48-9101-37050b74abd3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "cdbb9e4d-4dd9-4001-8b9c-4bc5f2453d14",
                    "activityIds": [
                      "1febba99-cf83-4f48-9101-37050b74abd3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "4e6724ad-55f0-483c-8b33-32b6d7fffbe4",
                    "activityIds": [
                      "fdeb2056-947d-44b2-a902-afdaefcd5ef1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "ee9d0487-6c4f-47b3-99c7-38f4dc0f24d9",
                    "activityIds": [
                      "fdeb2056-947d-44b2-a902-afdaefcd5ef1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "3f42b899-7e28-468c-a975-de1783914e5d",
                    "activityIds": [
                      "18680370-6717-4edc-bd44-a6573dbd1565"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "4ae1a8be-4f43-4f63-b910-21ba17cb8aca",
                    "activityIds": [
                      "18680370-6717-4edc-bd44-a6573dbd1565"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "6c3ad7f3-f51e-4973-a82a-b5e6e49ee2ca",
                    "activityIds": [
                      "6f4b0f11-ff5c-44e7-aada-8692833ff657"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "9c880f51-1dc2-4760-8030-2f9b7538a392",
                    "activityIds": [
                      "0535dc73-0192-4414-aa60-3d6aeabea23b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "c063b844-2f8f-47e7-944f-c0079082c707",
                    "activityIds": [
                      "0535dc73-0192-4414-aa60-3d6aeabea23b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "a777eaa8-64f0-4079-91fb-cd6df37e0669",
                    "activityIds": [
                      "0535dc73-0192-4414-aa60-3d6aeabea23b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "b6e00a22-0bc5-476b-9271-8aade0b792a9",
                    "activityIds": [
                      "0535dc73-0192-4414-aa60-3d6aeabea23b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "a99762fa-5a75-403f-91c3-2a866864cd5f",
                    "activityIds": [
                      "35e38ea1-d1d9-4430-adfa-d00b3cb162fa"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "80a80680-4c44-453f-a150-183a8d34387a",
                    "activityIds": [
                      "35e38ea1-d1d9-4430-adfa-d00b3cb162fa"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "edcca451-08ff-4404-b8aa-c80f39d74112",
                    "activityIds": [
                      "fffbe644-8996-4f78-a961-8447d2ad7ef5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "b27b11f1-270a-4472-a924-354759b82389",
                    "activityIds": [
                      "fffbe644-8996-4f78-a961-8447d2ad7ef5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_2",
                    "encounterId": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3"
                  },
                  {
                    "id": "c74c519f-1ff2-4139-bf65-c6b666766a2f",
                    "activityIds": [
                      "fffbe644-8996-4f78-a961-8447d2ad7ef5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_5",
                    "encounterId": "192c5a1b-9297-4a63-9e18-2df52dc4d3a4"
                  },
                  {
                    "id": "4ca841e7-f428-4ab6-b7f5-3537b5eaad03",
                    "activityIds": [
                      "fffbe644-8996-4f78-a961-8447d2ad7ef5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "e8489246-1a9a-4c7b-b703-5af6614a6af2",
                    "activityIds": [
                      "eef8f0df-911c-4f90-aa09-5edf5e5b606f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_24@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "0c8d7bde-2d38-48f1-a7f6-6547e4d8f6e6",
                    "activityIds": [
                      "dd88ad64-d01e-43e2-88a1-6acf650a5709"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_2",
                    "encounterId": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3"
                  },
                  {
                    "id": "f522bf09-47e4-4f08-a043-dc9bae1615bc",
                    "activityIds": [
                      "1aaf0d62-b31c-477c-b4a8-1aa577f6d3c8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_26@enc_2",
                    "encounterId": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3"
                  },
                  {
                    "id": "85165b00-0636-4462-8fd9-767b0c15ead6",
                    "activityIds": [
                      "eac96498-cb86-4868-9068-4c0556f468cc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_27@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "28a7322f-26de-41fb-a029-c969f2a14ffe",
                    "activityIds": [
                      "eac96498-cb86-4868-9068-4c0556f468cc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_27@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "593e8dc2-7120-4e7d-a20f-7549ae103871",
                    "activityIds": [
                      "eac96498-cb86-4868-9068-4c0556f468cc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_27@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "512804ce-c7b7-4c95-98c3-5894611f944e",
                    "activityIds": [
                      "eac96498-cb86-4868-9068-4c0556f468cc"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_27@enc_8",
                    "encounterId": "49cf6ca9-8d84-4de7-a753-1014928e11c4"
                  },
                  {
                    "id": "e1ed2102-a909-4654-bcf6-38ee95c6cb10",
                    "activityIds": [
                      "ad2f7cd8-482a-42a5-889e-2a3cc4af8b33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "b96a8d95-f0d2-476e-a09e-14dc0e6aa8ae",
                    "activityIds": [
                      "ad2f7cd8-482a-42a5-889e-2a3cc4af8b33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "c820ca32-f566-4fd0-8bd8-cec1feace9e9",
                    "activityIds": [
                      "34506df5-2660-4308-8869-b3da6650c124"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_2",
                    "encounterId": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3"
                  },
                  {
                    "id": "1f992146-45b0-43e0-b772-5544406e139b",
                    "activityIds": [
                      "a9900f5e-6085-44bb-9c23-08fecec2911f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_30@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "f8962af0-8aa8-43f0-a5c1-0c217fe0d3ee",
                    "activityIds": [
                      "a9900f5e-6085-44bb-9c23-08fecec2911f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_30@enc_7",
                    "encounterId": "0b29af1c-9607-40a4-bb4d-749e221e57af"
                  },
                  {
                    "id": "37551be3-983c-4663-81cb-3a2eadb84ba2",
                    "activityIds": [
                      "a9900f5e-6085-44bb-9c23-08fecec2911f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_30@enc_8",
                    "encounterId": "49cf6ca9-8d84-4de7-a753-1014928e11c4"
                  },
                  {
                    "id": "494899ba-a143-49ed-ad06-37f8f7629ba1",
                    "activityIds": [
                      "3f4a9f38-728f-4603-b319-5f7bcff13d7b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_31@enc_1",
                    "encounterId": "807432cf-8100-4222-86dc-31c63dd38650"
                  },
                  {
                    "id": "7eda3290-f418-4ad5-9146-3f533c7592ce",
                    "activityIds": [
                      "c3f27812-373a-4a3f-a9fb-df61af04c901"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_32@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "211ea1dd-890b-4f96-85ba-117cd07df26b",
                    "activityIds": [
                      "c3f27812-373a-4a3f-a9fb-df61af04c901"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_32@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  },
                  {
                    "id": "db1cb3e3-2339-41bb-8686-d142b09f8208",
                    "activityIds": [
                      "ae83b7ba-bdce-4ae5-9475-4dfa66155ed4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_33@enc_3",
                    "encounterId": "a46734ea-e22d-446b-ae0b-aad2c7a8124c"
                  },
                  {
                    "id": "c6ff2bd8-ea38-4efa-a30c-b5e6b42ac4aa",
                    "activityIds": [
                      "ae83b7ba-bdce-4ae5-9475-4dfa66155ed4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_33@enc_6",
                    "encounterId": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5"
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "807432cf-8100-4222-86dc-31c63dd38650",
                "name": "Screening (Days -28 to -2)",
                "instanceType": "Encounter",
                "type": {
                  "id": "d06a1e75-696c-4030-b74b-76564455ea5a",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "994d6a34-4a13-488b-a4cf-40ecc6bda61f"
              },
              {
                "id": "8d34dcfe-c976-4d6b-8ade-365bb29ebfb3",
                "name": "Screening (Day -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "6f10ece3-5f73-449d-8a73-cdf338e5271a",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "994d6a34-4a13-488b-a4cf-40ecc6bda61f"
              },
              {
                "id": "a46734ea-e22d-446b-ae0b-aad2c7a8124c",
                "name": "Period 1 (Day 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "26dc21d6-b522-4801-9a71-82d46d424bc4",
                  "code": "C82517",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline",
                  "instanceType": "Code"
                },
                "epochId": "fae0d8e6-e487-4435-b3d0-fbf6e0965f1f"
              },
              {
                "id": "0e9532a0-a494-46ed-b80d-9753cbe4afb1",
                "name": "Wash out (3 to 14 days)",
                "instanceType": "Encounter",
                "type": {
                  "id": "b5368322-5e4f-4e57-94fa-9ef996ed08d6",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "1ed1434e-0ed2-4c1b-8712-457199602601"
              },
              {
                "id": "192c5a1b-9297-4a63-9e18-2df52dc4d3a4",
                "name": "Period 2 (Day -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "2805a546-6aa2-45b5-afd6-5efc8cdaf048",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "1e3906cc-011f-4e77-a77e-c405382c8bee"
              },
              {
                "id": "3914b015-42ab-4c9b-bb31-b3e1d91dd6c5",
                "name": "Period 2 (Day 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "abc7f38f-0854-4930-b8b1-398fbdcba6e7",
                  "code": "C82517",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline",
                  "instanceType": "Code"
                },
                "epochId": "1e3906cc-011f-4e77-a77e-c405382c8bee"
              },
              {
                "id": "0b29af1c-9607-40a4-bb4d-749e221e57af",
                "name": "Follow-up/ED (Within 282 days)",
                "instanceType": "Encounter",
                "type": {
                  "id": "d804cdf1-a201-4ee1-a7df-0af0a04835c7",
                  "code": "C99158",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up",
                  "instanceType": "Code"
                },
                "epochId": "464bb227-fab8-4a4b-892b-2cc16dd24cb8"
              },
              {
                "id": "49cf6ca9-8d84-4de7-a753-1014928e11c4",
                "name": "Additional Follow-up for TE ADA",
                "instanceType": "Encounter",
                "type": {
                  "id": "7f1573a2-29e9-4c7e-a252-770b5039037f",
                  "code": "C99158",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up",
                  "instanceType": "Code"
                },
                "epochId": "7df14520-e41e-4154-9fb5-f5048e75be8a"
              }
            ],
            "activities": [
              {
                "id": "69cc0075-fec8-47ae-9f15-1d43bfb515c4",
                "name": "Clinical Assessments",
                "instanceType": "Activity",
                "childIds": [
                  "982149fc-8c0a-474e-b733-76cffae5fe4b",
                  "d060dd8d-1d07-44b1-87fa-95952282a885",
                  "ea0b3c03-0fc8-48c1-87ed-accc19e67c61",
                  "276e4f65-6e06-4f80-876b-f1f3b0070fc6",
                  "5b23d146-5158-4a9b-8da0-6fb3f1b00ca2",
                  "d5b31513-9642-4aae-a4d5-d4a74f87718d",
                  "64d68d45-2a38-4ae7-9012-7aabcf9f5c2f",
                  "c616b64d-abe1-4472-b41f-d79db7bd61e4",
                  "00001555-e6d7-47d4-a7f4-b6c00eecdf50",
                  "90898c34-49e3-4479-be83-ba1a94f8b915",
                  "997da135-d078-44a3-8b08-57cc6d056f2a",
                  "0128a51d-c4d3-4a46-9eea-8556f0a958c2",
                  "18d50b7a-c5f1-4efe-8ca8-cf92985c7980",
                  "1757c44f-8cb5-45e6-bde1-5011f27eaf7f",
                  "b6ccc49d-46ef-43b1-86f7-41950a4433cc",
                  "32e71b97-f083-41e6-a4b6-ea523dd73677",
                  "1febba99-cf83-4f48-9101-37050b74abd3",
                  "fdeb2056-947d-44b2-a902-afdaefcd5ef1",
                  "18680370-6717-4edc-bd44-a6573dbd1565"
                ]
              },
              {
                "id": "82d90057-e376-42a7-9fab-3368bc1f0eb3",
                "name": "Laboratory Tests",
                "instanceType": "Activity",
                "childIds": [
                  "6f4b0f11-ff5c-44e7-aada-8692833ff657",
                  "0535dc73-0192-4414-aa60-3d6aeabea23b",
                  "35e38ea1-d1d9-4430-adfa-d00b3cb162fa",
                  "fffbe644-8996-4f78-a961-8447d2ad7ef5",
                  "eef8f0df-911c-4f90-aa09-5edf5e5b606f",
                  "dd88ad64-d01e-43e2-88a1-6acf650a5709",
                  "1aaf0d62-b31c-477c-b4a8-1aa577f6d3c8",
                  "eac96498-cb86-4868-9068-4c0556f468cc",
                  "ad2f7cd8-482a-42a5-889e-2a3cc4af8b33",
                  "34506df5-2660-4308-8869-b3da6650c124",
                  "a9900f5e-6085-44bb-9c23-08fecec2911f"
                ],
                "extensionAttributes": [
                  {
                    "id": "a0f6d949-72f1-4abd-8600-fad3772d5d66",
                    "url": "https://protocol2usdm.io/extensions/x-executionModel-executionType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "{\"activityId\": \"Laboratory Tests\", \"executionType\": \"Window\", \"rationale\": \"WINDOW signals: 1; SINGLE signals: 1\"}"
                  }
                ]
              },
              {
                "id": "26c63535-d696-4fb3-94da-918639f84b3c",
                "name": "Health Outcome Instruments",
                "instanceType": "Activity",
                "childIds": [
                  "3f4a9f38-728f-4603-b319-5f7bcff13d7b",
                  "c3f27812-373a-4a3f-a9fb-df61af04c901",
                  "ae83b7ba-bdce-4ae5-9475-4dfa66155ed4"
                ]
              },
              {
                "id": "982149fc-8c0a-474e-b733-76cffae5fe4b",
                "name": "Informed Consent",
                "instanceType": "Activity",
                "description": "Informed Consent"
              },
              {
                "id": "d060dd8d-1d07-44b1-87fa-95952282a885",
                "name": "Randomization",
                "instanceType": "Activity",
                "description": "Randomization"
              },
              {
                "id": "ea0b3c03-0fc8-48c1-87ed-accc19e67c61",
                "name": "Admission to CRU",
                "instanceType": "Activity",
                "description": "Admission can be rescheduled if PG level is not 90 to 250 mg/dL on Day 1."
              },
              {
                "id": "276e4f65-6e06-4f80-876b-f1f3b0070fc6",
                "name": "Discharge from CRU",
                "instanceType": "Activity",
                "description": "Patient may be discharged 6 hours after glucagon administration. A patient may remain inpatient at the CRU at the discretion of the investigator."
              },
              {
                "id": "5b23d146-5158-4a9b-8da0-6fb3f1b00ca2",
                "name": "Medical History",
                "instanceType": "Activity",
                "description": "Medical History"
              },
              {
                "id": "d5b31513-9642-4aae-a4d5-d4a74f87718d",
                "name": "Collect Pre-existing Conditions and Adverse Events",
                "instanceType": "Activity",
                "description": "Collect Pre-existing Conditions and Adverse Events"
              },
              {
                "id": "64d68d45-2a38-4ae7-9012-7aabcf9f5c2f",
                "name": "Physical Exam",
                "instanceType": "Activity",
                "description": "After screening, medical assessment only performed to include medical review and targeted examination, as appropriate."
              },
              {
                "id": "c616b64d-abe1-4472-b41f-d79db7bd61e4",
                "name": "Height and Weight",
                "instanceType": "Activity",
                "description": "Height is at screening only. Weight on Day 1 will be collected before the start of the procedure to induce hypoglycemia."
              },
              {
                "id": "00001555-e6d7-47d4-a7f4-b6c00eecdf50",
                "name": "Collect Hypoglycemic Events",
                "instanceType": "Activity",
                "description": "Refer to Section 9.5.5.1."
              },
              {
                "id": "90898c34-49e3-4479-be83-ba1a94f8b915",
                "name": "Collect Concomitant Medications",
                "instanceType": "Activity",
                "description": "Review patients insulin regimens to confirm acceptability to undergo the procedure to induce hypoglycemia."
              },
              {
                "id": "997da135-d078-44a3-8b08-57cc6d056f2a",
                "name": "Meal",
                "instanceType": "Activity",
                "description": "After completion of all PK sampling, patients will be provided a carbohydrate-rich meal. The investigator will ensure the patients PG is stable. A prandial insulin dose will be administered if needed."
              },
              {
                "id": "0128a51d-c4d3-4a46-9eea-8556f0a958c2",
                "name": "Insulin infusion to Induce Hypoglycemia",
                "instanceType": "Activity",
                "description": "Procedures in Period 2 will occur at approximately the same time as those in Period 1. Insulin infusion is stopped once bedside PG is <60 mg/dL."
              },
              {
                "id": "18d50b7a-c5f1-4efe-8ca8-cf92985c7980",
                "name": "Bedside PG Monitoring for Safety",
                "instanceType": "Activity",
                "description": "Samples will be collected during the hypoglycemia induction procedure and post study treatment (up to 120 mins). Bedside PG monitoring will be conducted no more than 10 minutes apart while bedside PG is 90 mg/dL and no more than 5 minutes apart when bedside PG is <90 mg/dL."
              },
              {
                "id": "1757c44f-8cb5-45e6-bde1-5011f27eaf7f",
                "name": "Study Treatment Administration",
                "instanceType": "Activity",
                "description": "Once bedside PG reaches <60 mg/dL, the insulin infusion is stopped and approximately 5 minutes later study drug is administered. Indicates Time = 0 min."
              },
              {
                "id": "b6ccc49d-46ef-43b1-86f7-41950a4433cc",
                "name": "Injection-Site Assessment",
                "instanceType": "Activity",
                "description": "Injection-site assessment for IMG only."
              },
              {
                "id": "32e71b97-f083-41e6-a4b6-ea523dd73677",
                "name": "Nasal Inspection",
                "instanceType": "Activity",
                "description": "Nasal inspection both for IMG and LY900018."
              },
              {
                "id": "1febba99-cf83-4f48-9101-37050b74abd3",
                "name": "Vital Signs (Supine Blood Pressure, Pulse Rate, and Body Temperature)",
                "instanceType": "Activity",
                "description": "Time points may be added for each period if warranted and agreed upon between Lilly and the investigator. Predose time point will be between insulin infusion stop and study treatment."
              },
              {
                "id": "fdeb2056-947d-44b2-a902-afdaefcd5ef1",
                "name": "Single 12-lead ECG (Local)",
                "instanceType": "Activity",
                "description": "Single 12-lead ECG (Local)"
              },
              {
                "id": "18680370-6717-4edc-bd44-a6573dbd1565",
                "name": "Triplicate 12-lead ECG (Central)",
                "instanceType": "Activity",
                "description": "Time points may be added for Period 1 and Period 2 if warranted and agreed upon between Lilly and the investigator. Predose time point will be between insulin infusion stop and study treatment."
              },
              {
                "id": "6f4b0f11-ff5c-44e7-aada-8692833ff657",
                "name": "Clinical Serology Tests",
                "instanceType": "Activity",
                "description": "See Appendix 2, Clinical Laboratory Tests, for details."
              },
              {
                "id": "0535dc73-0192-4414-aa60-3d6aeabea23b",
                "name": "Clinical Lab Tests (Hematology, Clinical Chemistry, and Urinalysis)",
                "instanceType": "Activity",
                "description": "See Appendix 2, Clinical Laboratory Tests, for details. Patients do not need to fast for samples at screening or follow-up. At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures."
              },
              {
                "id": "35e38ea1-d1d9-4430-adfa-d00b3cb162fa",
                "name": "HbA1c",
                "instanceType": "Activity",
                "description": "See Appendix 2, Clinical Laboratory Tests, for details."
              },
              {
                "id": "fffbe644-8996-4f78-a961-8447d2ad7ef5",
                "name": "Pregnancy Test (Female patients of childbearing potential only)",
                "instanceType": "Activity",
                "description": "Serum pregnancy test will be performed at screening. Urine pregnancy test will be performed at every admission period and follow-up visit if applicable."
              },
              {
                "id": "eef8f0df-911c-4f90-aa09-5edf5e5b606f",
                "name": "FSH (Female patients only)",
                "instanceType": "Activity",
                "description": "When needed to confirm postmenopausal status."
              },
              {
                "id": "dd88ad64-d01e-43e2-88a1-6acf650a5709",
                "name": "Ethanol Testing",
                "instanceType": "Activity",
                "description": "Additional tests can be done at the discretion of the investigator."
              },
              {
                "id": "1aaf0d62-b31c-477c-b4a8-1aa577f6d3c8",
                "name": "Urine Drug Screen",
                "instanceType": "Activity",
                "description": "Additional tests can be done at the discretion of the investigator."
              },
              {
                "id": "eac96498-cb86-4868-9068-4c0556f468cc",
                "name": "PK (Glucagon)",
                "instanceType": "Activity",
                "description": "Sampling times are relative to the time of study treatment administration (0 min). Predose time point will be between insulin infusion stop and study treatment."
              },
              {
                "id": "ad2f7cd8-482a-42a5-889e-2a3cc4af8b33",
                "name": "Plasma Glucose for PD",
                "instanceType": "Activity",
                "description": "-5 mins = stop insulin infusion. Sampling times are relative to the time of study treatment administration (0 min). Predose time point will be between insulin infusion stop and study treatment."
              },
              {
                "id": "34506df5-2660-4308-8869-b3da6650c124",
                "name": "Genetic Sample (Stored)",
                "instanceType": "Activity",
                "description": "Single sample for pharmacogenetic analysis taken prior to/on Period 1 Day -1."
              },
              {
                "id": "a9900f5e-6085-44bb-9c23-08fecec2911f",
                "name": "Anti-glucagon Antibodies",
                "instanceType": "Activity",
                "description": "In the event of drug hypersensitivity reactions (immediate or non-immediate), samples will be collected as close to event onset as possible, at event resolution, and 30 days following the event. Patients with TE ADA at follow-up/ED will undergo additional follow-up. Refer to Section 9.7.1 for details."
              },
              {
                "id": "3f4a9f38-728f-4603-b319-5f7bcff13d7b",
                "name": "Clarke Hypoglycemia Awareness Survey",
                "instanceType": "Activity",
                "description": "Clarke Hypoglycemia Awareness Survey"
              },
              {
                "id": "c3f27812-373a-4a3f-a9fb-df61af04c901",
                "name": "Nasal and Non-nasal Score Questionnaire",
                "instanceType": "Activity",
                "description": "Sampling times are relative to the time of study treatment administration (0 min). Questionnaire will be collected in both LY900018 and IMG treatment groups in both periods."
              },
              {
                "id": "ae83b7ba-bdce-4ae5-9475-4dfa66155ed4",
                "name": "Edinburgh Hypoglycemia Scale: Experimental Hypoglycemia",
                "instanceType": "Activity",
                "description": "Sampling times are relative to the time of study treatment administration (0 min). During hypoglycemia induction will be when PG 75 mg/dL. Predose time point will be between insulin infusion stop and study treatment."
              }
            ],
            "epochs": [
              {
                "id": "994d6a34-4a13-488b-a4cf-40ecc6bda61f",
                "name": "Screening",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "70042482-7e98-408f-98a4-d4ed2d5d0f96",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "fae0d8e6-e487-4435-b3d0-fbf6e0965f1f",
                "name": "Period 1",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "16a37689-e690-4689-9fd4-2cdad6b9f990",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "1ed1434e-0ed2-4c1b-8712-457199602601",
                "name": "Wash out",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "8ecee8c7-f544-42ab-b65e-d1fcc21b118b",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "1e3906cc-011f-4e77-a77e-c405382c8bee",
                "name": "Period 2",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "6788ec4f-3da6-4ef4-8d59-4f2268f94738",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "464bb227-fab8-4a4b-892b-2cc16dd24cb8",
                "name": "Follow-up/ED",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "6063720a-4946-49d4-a3b5-4eb31455240e",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "7df14520-e41e-4154-9fb5-f5048e75be8a",
                "name": "Additional Follow-up for TE ADAa",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "bad7c44f-36e6-4ee4-aeaa-6ad3d94c15a6",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Epoch",
                  "instanceType": "Code"
                }
              }
            ],
            "notes": [
              {
                "id": "b167b3f4-62dc-41d4-9554-ae9d31204527",
                "text": "Abbreviations: CRU = clinical research unit; ECG = electrocardiogram; ED = early discontinuation; FSH = follicle-stimulating hormone; HbA1c = hemoglobin A1c; IMG =intramuscular glucagon; min = minutes; PD = pharmacodynamics; PG = plasma glucose; PK = pharmacokinetics; TE ADA = treatment-emergent antidrug antibodies.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "5a8d5be8-b262-40c9-bfc9-bb01becbfcad",
                "text": "a. Samples for immunogenicity, should be collected every 12 weeks (847 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of the baseline titer) or until 1 year after the last dose of study treatment. A time-matched PK (glucagon) sample may be collected at the follow-up immunogenicity assessment(s) if warranted and agreed upon between both the investigator and sponsor.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "bf99ae3d-dafd-4701-a3f0-b35579d59b56",
                "text": "Note: If multiple procedures take place at the same time point, the following order of the procedure should be used: ECG, vital signs, and venipuncture. Plasma glucose sample should be collected as close as possible of protocol-specified time point.",
                "instanceType": "CommentAnnotation"
              }
            ],
            "model": {
              "id": "247e3a7f-c7f6-443c-be5d-1db793422de8",
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "extensionAttributes": [
              {
                "id": "1a235203-f756-4210-9293-477bced87ed3",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"anchor_llm_1\", \"definition\": \"Study treatment administration\", \"anchorType\": \"FirstDose\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Indicates Time = 0 min.\"}, {\"id\": \"anchor_1\", \"definition\": \"Screening visit\", \"anchorType\": \"Screening\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Screening\\nPeriod\"}, {\"id\": \"anchor_2\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Informed Consent\"}, {\"id\": \"anchor_3\", \"definition\": \"Procedure\", \"anchorType\": \"Custom\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"Procedure\"}]"
              },
              {
                "id": "4ead78ac-6282-4deb-8092-a56adc87f0b3",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"rep_daily_1\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"rep_interval_1\", \"type\": \"Interval\", \"sourceText\": \"tid\"}, {\"id\": \"rep_interval_5\", \"type\": \"Interval\", \"interval\": \"PT15M\", \"minObservations\": 5, \"sourceText\": \"Predose, 15, 30, \\n60, 120, 240 min\"}, {\"id\": \"rep_interval_9\", \"type\": \"Interval\", \"interval\": \"PT5M\", \"minObservations\": 12, \"sourceText\": \"Predose, 5, 10, 15, \\n20, 25, 30, 40, 50, \\n60, 90, 120, 240 \\nmin\"}, {\"id\": \"rep_interval_13\", \"type\": \"Interval\", \"interval\": \"PT15M\", \"minObservations\": 4, \"sourceText\": \"Predose, 15, 30, \\n60, 120 min\"}, {\"id\": \"rep_window_1\", \"type\": \"Continuous\", \"startOffset\": \"P28D\", \"endOffset\": \"P2D\", \"sourceText\": \"Days -28\\nto -2\"}, {\"id\": \"rep_window_5\", \"type\": \"Continuous\", \"sourceText\": \"washout period\"}, {\"id\": \"rep_window_6\", \"type\": \"Continuous\", \"sourceText\": \"Screening\\nPeriod\"}, {\"id\": \"rep_window_10\", \"type\": \"Continuous\", \"sourceText\": \"screening period\"}, {\"id\": \"rep_window_12\", \"type\": \"Continuous\", \"sourceText\": \"washout \\nperiod\"}, {\"id\": \"rep_window_13\", \"type\": \"Continuous\", \"sourceText\": \"treatment period\"}, {\"id\": \"rep_window_17\", \"type\": \"Continuous\", \"sourceText\": \"follow-up period\"}, {\"id\": \"rep_window_18\", \"type\": \"Continuous\", \"sourceText\": \"30 days after\"}, {\"id\": \"rep_window_19\", \"type\": \"Continuous\", \"sourceText\": \"2 days \\nafter\"}, {\"id\": \"rep_window_23\", \"type\": \"Continuous\", \"sourceText\": \"6 hours after\"}, {\"id\": \"rep_window_24\", \"type\": \"Continuous\", \"sourceText\": \"4 hours after\"}]"
              },
              {
                "id": "f463a7c1-a11f-4a11-b328-ffcd02330419",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-samplingConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"pk_sampling_1\", \"activityId\": \"PK_Blood_Sampling\", \"minPerWindow\": 4, \"windowDuration\": \"PT3H\", \"timepoints\": [\"15 minutes\", \"30 minutes\", \"60 minutes\", \"120 minutes\"], \"sourceText\": \"Predose, 15, 30, \\n60, 120 min\"}]"
              },
              {
                "id": "3654bf20-672f-4e96-a44f-e9707e4b420b",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-crossoverDesign",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"crossover_1\", \"isCrossover\": true, \"numPeriods\": 2, \"numSequences\": 2, \"periods\": [\"Period 1\", \"Period 2\"], \"sequences\": [\"AB\", \"BA\"], \"washoutDuration\": \"3 to 14 days\", \"washoutRequired\": true, \"carryoverPrevention\": \"Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days.\", \"sourceText\": \"crossover study\"}"
              },
              {
                "id": "71c6f8a6-77d4-4f97-bf35-07cf9d2de7b1",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"traversal_crossover_1\", \"requiredSequence\": [\"SCREENING\", \"PERIOD_1\", \"WASHOUT\", \"PERIOD_2\", \"END_OF_STUDY\"], \"allowEarlyExit\": true, \"exitEpochIds\": [\"EARLY_TERMINATION\"], \"mandatoryVisits\": [\"Screening\", \"Day 1\", \"End of Study\"], \"sourceText\": \"crossover study\"}, {\"id\": \"traversal_1\", \"requiredSequence\": [\"SCREENING\", \"BASELINE\", \"TREATMENT\", \"WASHOUT\", \"FOLLOW_UP\", \"END_OF_STUDY\"], \"allowEarlyExit\": true, \"exitEpochIds\": [\"EARLY_TERMINATION\"], \"mandatoryVisits\": [\"Treatment Visit (Insulin-induced Hypoglycemia and Glucagon Administration)\", \"End of Study\", \"Screening Visit\", \"Screening\", \"Day 1\", \"End of Study Visit\"], \"sourceText\": \"[{'condition': 'Insufficient response to glucagon administration', 'path': ['RESCUE_PROCEDURE']}, {'condition': 'Subject meets criteria for discontinuation from study treatment or the study', 'path': ['EARLY_TERMINATION']}]\"}]"
              },
              {
                "id": "443c282c-0cd4-4ef2-ac62-879493b55a3b",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"fn_cond_1\", \"conditionType\": \"frequency_daily\", \"text\": \"multiple daily injection of long-acting insulin analog\", \"footnoteId\": \"[A]\", \"sourceText\": \"multiple daily injection of long-acting insulin analog\"}, {\"id\": \"fn_cond_2\", \"conditionType\": \"timing_before\", \"text\": \"women of childbearing potential participating must test negative for \\npregnancy prior to initiation of treatment as indicated by a negative serum \\npregnancy test at the screening visit followed by a negative urine \\npregnancy test within\", \"footnoteId\": \"[A]\", \"sourceText\": \"women of childbearing potential participating must test negative for \\npregnancy prior to initiation \"}, {\"id\": \"fn_cond_3\", \"conditionType\": \"general\", \"text\": \"either one highly effective method of contraception or a combination \\nof\", \"footnoteId\": \"[B]\", \"sourceText\": \"either one highly effective method of contraception or a combination \\nof\"}, {\"id\": \"fn_cond_4\", \"conditionType\": \"general\", \"text\": \"postmenopausal, defined as either:\", \"footnoteId\": \"[B]\", \"sourceText\": \"postmenopausal, defined as either:\"}, {\"id\": \"fn_cond_5\", \"conditionType\": \"general\", \"text\": \"cessation of menses for at least\", \"footnoteId\": \"[a]\", \"sourceText\": \"cessation of menses for at least\"}, {\"id\": \"fn_cond_6\", \"conditionType\": \"general\", \"text\": \"if warranted and agreed upon between both the investigator and sponsor\", \"footnoteId\": \"(s)\", \"sourceText\": \"if warranted and agreed upon between both the investigator and sponsor\"}, {\"id\": \"fn_cond_7\", \"conditionType\": \"general\", \"text\": \"Predose time point will be\\nbetween insulin infusion \\nstop and study treatment\", \"footnoteId\": \"L.\", \"sourceText\": \"Predose time point will be\\nbetween insulin infusion \\nstop and study treatment\"}, {\"id\": \"fn_cond_8\", \"conditionType\": \"general\", \"text\": \"a\\nSamples for immunogenicity, should be collected every\", \"footnoteId\": \"s.\", \"sourceText\": \"a\\nSamples for immunogenicity, should be collected every\"}, {\"id\": \"fn_cond_9\", \"conditionType\": \"timing_after\", \"text\": \"Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, vital signs, and venipuncture\", \"footnoteId\": \"r.\", \"sourceText\": \"Note:  if multiple procedures take place at the same time point, the following order of the procedur\"}, {\"id\": \"fn_cond_10\", \"conditionType\": \"general\", \"text\": \"The nature of any conditions present at the time of the physical examination and any preexisting \\nconditions will be documented\", \"footnoteId\": \"G.\", \"sourceText\": \"The nature of any conditions present at the time of the physical examination and any preexisting \\nco\"}, {\"id\": \"fn_cond_11\", \"conditionType\": \"general\", \"text\": \"Patients who are not enrolled within\", \"footnoteId\": \"t.\", \"sourceText\": \"Patients who are not enrolled within\"}, {\"id\": \"fn_cond_12\", \"conditionType\": \"general\", \"text\": \"Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \\nprotocol waivers or exemptions, are not permitted\", \"footnoteId\": \"y.\", \"sourceText\": \"Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \\np\"}, {\"id\": \"fn_cond_13\", \"conditionType\": \"general\", \"text\": \"The patient may \\nchoose to use a double barrier method of contraception\", \"footnoteId\": \"d.\", \"sourceText\": \"The patient may \\nchoose to use a double barrier method of contraception\"}, {\"id\": \"fn_cond_14\", \"conditionType\": \"general\", \"text\": \"Thus, each barrier method must include use of a \\nspermicide\", \"footnoteId\": \"d.\", \"sourceText\": \"Thus, each barrier method must include use of a \\nspermicide\"}, {\"id\": \"fn_cond_15\", \"conditionType\": \"general\", \"text\": \"Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \\nwill be destroyed within\", \"footnoteId\": \"y.\", \"sourceText\": \"Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \\n\"}, {\"id\": \"fn_cond_16\", \"conditionType\": \"procedure_conditional\", \"text\": \"Certain samples may be \\nretained for a longer period, if necessary, to comply with applicable laws, regulations, or \\nlaboratory certification standards\", \"footnoteId\": \"s.\", \"sourceText\": \"Certain samples may be \\nretained for a longer period, if necessary, to comply with applicable laws, \"}, {\"id\": \"fn_cond_17\", \"conditionType\": \"timing_after\", \"text\": \"Blood pressure and pulse rate should be measured after at least\", \"footnoteId\": \"d.\", \"sourceText\": \"Blood pressure and pulse rate should be measured after at least\"}, {\"id\": \"fn_cond_18\", \"conditionType\": \"general\", \"text\": \"Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \\nposture-induced symptoms\", \"footnoteId\": \"e.\", \"sourceText\": \"Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \\n\"}, {\"id\": \"fn_cond_19\", \"conditionType\": \"general\", \"text\": \"If the patient feels unable to stand, supine \\nvital signs only will be recorded\", \"footnoteId\": \"s.\", \"sourceText\": \"If the patient feels unable to stand, supine \\nvital signs only will be recorded\"}, {\"id\": \"fn_cond_20\", \"conditionType\": \"general\", \"text\": \"Single ECGs will be collected and stored locally at the investigators site\", \"footnoteId\": \"F.\", \"sourceText\": \"Single ECGs will be collected and stored locally at the investigators site\"}, {\"id\": \"fn_cond_21\", \"conditionType\": \"general\", \"text\": \"The central ECG laboratory will perform a basic quality control check\", \"footnoteId\": \"y.\", \"sourceText\": \"The central ECG laboratory will perform a basic quality control check\"}, {\"id\": \"fn_cond_22\", \"conditionType\": \"general\", \"text\": \"At a future time, the stored \\nECG data may be overread at the central ECG laboratory for further evaluation of machine-read \\nmeasurements or to meet regulatory requirements\", \"footnoteId\": \"e.\", \"sourceText\": \"At a future time, the stored \\nECG data may be overread at the central ECG laboratory for further eva\"}, {\"id\": \"fn_cond_23\", \"conditionType\": \"general\", \"text\": \"Concentrations of glucagon will be assayed using a validated liquid chromatography with \\ntandem mass spectrometry method\", \"footnoteId\": \"r.\", \"sourceText\": \"Concentrations of glucagon will be assayed using a validated liquid chromatography with \\ntandem mass\"}, {\"id\": \"fn_cond_24\", \"conditionType\": \"general\", \"text\": \"The samples will be stored for up to a maximum of\", \"footnoteId\": \"s.\", \"sourceText\": \"The samples will be stored for up to a maximum of\"}, {\"id\": \"fn_cond_25\", \"conditionType\": \"general\", \"text\": \"To interpret the results of \\nimmunogenicity, a venous blood sample may be collected at the same time points to determine \\nthe concentrations of glucagon\", \"footnoteId\": \"n.\", \"sourceText\": \"To interpret the results of \\nimmunogenicity, a venous blood sample may be collected at the same time\"}, {\"id\": \"fn_cond_26\", \"conditionType\": \"general\", \"text\": \"A PK sample may be collected at these \\nsame time points\", \"footnoteId\": \"t.\", \"sourceText\": \"A PK sample may be collected at these \\nsame time points\"}, {\"id\": \"fn_cond_27\", \"conditionType\": \"general\", \"text\": \"Treatment-emergent antidrug antibodies\", \"footnoteId\": \"r.\", \"sourceText\": \"Treatment-emergent antidrug antibodies\"}, {\"id\": \"fn_cond_28\", \"conditionType\": \"general\", \"text\": \"A PK \\nsample may be collected at the follow-up immunogenicity assessment\", \"footnoteId\": \"t.\", \"sourceText\": \"A PK \\nsample may be collected at the follow-up immunogenicity assessment\"}, {\"id\": \"fn_cond_29\", \"conditionType\": \"general\", \"text\": \"Every attempt should be made to contact \\npatients for the follow-up immunogenicity assessment; however, if patients are unwilling or \\nunable to return for the visit, this is not considered a protocol violation\", \"footnoteId\": \"r.\", \"sourceText\": \"Every attempt should be made to contact \\npatients for the follow-up immunogenicity assessment; howev\"}, {\"id\": \"fn_cond_30\", \"conditionType\": \"general\", \"text\": \"male patients: agree to use an effective method of contraception for the \\nduration of the study and for\", \"footnoteId\": \"[2]\", \"sourceText\": \"male patients: agree to use an effective method of contraception for the \\nduration of the study and \"}, {\"id\": \"fn_cond_31\", \"conditionType\": \"general\", \"text\": \"female patients:\", \"footnoteId\": \"[3]\", \"sourceText\": \"female patients:\"}, {\"id\": \"fn_cond_32\", \"conditionType\": \"general\", \"text\": \"Study Population\\nEligibility of patients for the study will be based on the results of screening medical history, \\nphysical examination, vital signs, clinical laboratory tests, and ECG\", \"footnoteId\": \"6.\", \"sourceText\": \"Study Population\\nEligibility of patients for the study will be based on the results of screening med\"}, {\"id\": \"fn_cond_33\", \"conditionType\": \"timing_after\", \"text\": \"Inclusion Criteria\\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \\nscreening and/or enrollment:\", \"footnoteId\": \"1.\", \"sourceText\": \"Inclusion Criteria\\nPatients are eligible for inclusion in the study only if they meet all of the fol\"}, {\"id\": \"fn_cond_34\", \"conditionType\": \"general\", \"text\": \"Study Assessments and Procedures\\nSection\", \"footnoteId\": \"9.\", \"sourceText\": \"Study Assessments and Procedures\\nSection\"}, {\"id\": \"fn_cond_35\", \"conditionType\": \"general\", \"text\": \"Efficacy Assessments\\nPlasma glucose levels will be measured as described in Section\", \"footnoteId\": \"1.\", \"sourceText\": \"Efficacy Assessments\\nPlasma glucose levels will be measured as described in Section\"}, {\"id\": \"fn_cond_36\", \"conditionType\": \"general\", \"text\": \"Primary Efficacy Assessments\\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \\nas either an increase in PG to >\", \"footnoteId\": \"1.\", \"sourceText\": \"Primary Efficacy Assessments\\nThe primary efficacy measure is the proportion of patients achieving tr\"}, {\"id\": \"fn_cond_37\", \"conditionType\": \"general\", \"text\": \"Secondary Efficacy Assessments\\nSecondary efficacy measures will be determined from the pharmacodynamic\", \"footnoteId\": \"2.\", \"sourceText\": \"Secondary Efficacy Assessments\\nSecondary efficacy measures will be determined from the pharmacodynam\"}, {\"id\": \"fn_cond_38\", \"conditionType\": \"general\", \"text\": \"Exploratory Efficacy Assessments\\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool\", \"footnoteId\": \"3.\", \"sourceText\": \"Exploratory Efficacy Assessments\\nSubjective hypoglycemia symptoms will be assessed using a self-repo\"}, {\"id\": \"fn_cond_39\", \"conditionType\": \"general\", \"text\": \"Insulin-induced Hypoglycemia\\nA study investigator, or qualified designee, must be present at the bedside for clinical \\nassessments of the patient during the insulin infusion and for the\", \"footnoteId\": \"1.\", \"sourceText\": \"Insulin-induced Hypoglycemia\\nA study investigator, or qualified designee, must be present at the bed\"}, {\"id\": \"fn_cond_40\", \"conditionType\": \"general\", \"text\": \"Treatment of Overdose\\nFor the purposes of this study, an overdose of LY\", \"footnoteId\": \"4.\", \"sourceText\": \"Treatment of Overdose\\nFor the purposes of this study, an overdose of LY\"}, {\"id\": \"fn_cond_41\", \"conditionType\": \"general\", \"text\": \"Laboratory Tests\\nFor each patient, laboratory tests detailed in Appendix\", \"footnoteId\": \"1.\", \"sourceText\": \"Laboratory Tests\\nFor each patient, laboratory tests detailed in Appendix\"}, {\"id\": \"fn_cond_42\", \"conditionType\": \"general\", \"text\": \"Vital Signs\\nFor each patient, vital sign measurements should be conducted according to the Schedule of \\nActivities\", \"footnoteId\": \"2.\", \"sourceText\": \"Vital Signs\\nFor each patient, vital sign measurements should be conducted according to the Schedule \"}, {\"id\": \"fn_cond_43\", \"conditionType\": \"general\", \"text\": \"Electrocardiograms\\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \\nActivities\", \"footnoteId\": \"3.\", \"sourceText\": \"Electrocardiograms\\nFor each patient, single and triplicate ECGs should be collected according to the\"}, {\"id\": \"fn_cond_44\", \"conditionType\": \"general\", \"text\": \"Bioanalysis\\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facility \\ndesignated by the sponsor\", \"footnoteId\": \"1.\", \"sourceText\": \"Bioanalysis\\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facilit\"}, {\"id\": \"fn_cond_45\", \"conditionType\": \"general\", \"text\": \"Pharmacodynamics\\nAt times specified in the Schedule of Activities\", \"footnoteId\": \"7.\", \"sourceText\": \"Pharmacodynamics\\nAt times specified in the Schedule of Activities\"}, {\"id\": \"fn_cond_46\", \"conditionType\": \"general\", \"text\": \"Immunogenicity Assessments\\nAt the visits and times specified in the Schedule of Activities\", \"footnoteId\": \"1.\", \"sourceText\": \"Immunogenicity Assessments\\nAt the visits and times specified in the Schedule of Activities\"}, {\"id\": \"fn_cond_47\", \"conditionType\": \"general\", \"text\": \"If the \\nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \\ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \\nback to the site for follow-up immunogenicity assessment\", \"footnoteId\": \"6.\", \"sourceText\": \"If the \\nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \\nde\"}]"
              },
              {
                "id": "bd601ef6-bc6c-4112-a132-5d074e3ea6f7",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"ep_1\", \"name\": \"Exploratory Endpoint 1\", \"endpointType\": \"Exploratory\", \"inputs\": [\"PR\", \"CR\", \"OS\", \"PG\", \"glucose\", \"is the\", \"efficacy outcomes\", \"insulin\"], \"timeWindow\": {\"reference\": \"nadir within\", \"duration\": \"P60D\"}, \"algorithm\": \"either an increase in pg to >70 mg/dl or an increase of >20 mg/dl from nadir within \\n30 minutes after administration of glucagon\", \"successCriteria\": \"treatment success, defined \\nas either an increase in pg to >70 mg/dl or an increase of >20 mg/dl from nadir within \\n30 minutes after administration of glucagon\", \"unit\": \"mg/dl\", \"sourceText\": \"--- Page 36 ---\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 35\\nLY900018\\n9. Study Assessments and Procedures\\nSection 2 lists the Schedule of Activities, detailing the study procedures and their \"}, {\"id\": \"ep_2\", \"name\": \"is to demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the \\nproportion (NIM=10%) of Ja\", \"endpointType\": \"Primary\", \"inputs\": [\"PR\", \"CR\", \"OS\", \"PG\", \"glucose\", \"to raise\", \"treatment success\"], \"timeWindow\": {\"reference\": \"pg nadir\", \"duration\": \"PT30M\"}, \"algorithm\": \"either an increase in pg to 70 mg/dl or an increase of 20 mg/dl from pg nadir \\nwithin 30 minutes after receiving study treatment\", \"successCriteria\": \"either an increase in pg to 70 mg/dl or an increase of 20 mg/dl from pg nadir \\nwithin 30 minutes after receiving study treatment\", \"unit\": \"mg\", \"sourceText\": \"primary objective is to demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the \\nproportion (NIM=10%) of Japanese patients with T1DM or T2DM who achieve treatment \\nsuccess without receiving\"}]"
              },
              {
                "id": "f8d6c7aa-b0b8-4b61-8b81-1821ada916a6",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dv_1\", \"name\": \"PG concentrations\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"actual time\", \"wilcoxon signed\", \"concentrations of\", \"creatinine\", \"clarke hypoglycemia\", \"preferred terms\", \"standard noncompartmental\", \"baseline\", \"glucose\", \"observed medians\", \"AST\", \"ALT\", \"standard \\ndescriptive\", \"hemoglobin\", \"consultation with\", \"descriptive methodology\", \"nca\", \"HbA1c\", \"a self\"], \"derivationRule\": \"the sum of the scores for each question\", \"baselineVisit\": \"day\\n-1\", \"analysisWindow\": \"day 1\", \"unit\": \"described\", \"sourceText\": \"--- Page 19 ---\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 18\\nLY900018\\nScreening\\nPeriod 1\\nWash \\nout\\nPeriod 2\\nFollow-up/ED\\nAdditional \\nFollow-up for \\nTE ADAa\\nComments\\nProcedure\\nDays -28\\nto -2\\nD\"}, {\"id\": \"dv_2\", \"name\": \"concentrations of\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"glucose\", \"change from\"], \"derivationRule\": \"post_value - baseline_value\", \"sourceText\": \"\\n1.5 hours\\n\\n\\n--- Page 51 ---\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 50\\nLY900018\\nBGmax\\nmaximal plasma glucose concentration\\nDurationabove\\nduration above normal range\\nDurationbelow\\nduration \"}, {\"id\": \"dv_3\", \"name\": \"may be\", \"variableType\": \"Custom\", \"sourceVariables\": [\"glucose\", \"HbA1c\", \"AST\", \"wilcoxon signed\"], \"derivationRule\": \"210 minutes per period/3 = 70 samples per period  2 periods = 140 samples total\", \"baselineVisit\": \"screening\", \"unit\": \"90\", \"sourceText\": \"\\n1.5 hours\\nBGmax\\nmaximal plasma glucose concentration\\nTmax\\ntime to maximal concentration\\nBaseline PG concentrations will be concentrations from samples obtained immediately prior to \\nglucagon dosing (\"}]"
              },
              {
                "id": "c502362e-6742-463c-bf69-40c56366b040",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"sm_1\", \"initialState\": \"Screening\", \"terminalStates\": [\"Completed\", \"Discontinued\", \"Withdrawn\", \"Death\", \"LostToFollowUp\"], \"states\": [\"Screening\", \"Enrolled\", \"OnTreatment\", \"FollowUp\", \"Completed\", \"Discontinued\", \"Withdrawn\", \"Death\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Enrolled\", \"trigger\": \"Progress from Screening to Enrolled\"}, {\"fromState\": \"Enrolled\", \"toState\": \"OnTreatment\", \"trigger\": \"Progress from Enrolled to OnTreatment\"}, {\"fromState\": \"OnTreatment\", \"toState\": \"FollowUp\", \"trigger\": \"Progress from OnTreatment to FollowUp\"}, {\"fromState\": \"FollowUp\", \"toState\": \"Completed\", \"trigger\": \"Progress from FollowUp to Completed\"}, {\"fromState\": \"OnTreatment\", \"toState\": \"Discontinued\", \"trigger\": \"Discontinuation from treatment\"}, {\"fromState\": \"OnTreatment\", \"toState\": \"OnTreatment\", \"trigger\": \"Enter washout period\", \"guardCondition\": \"period_complete AND NOT last_period\"}]}"
              },
              {
                "id": "f0d5e641-4de7-4e87-8f44-68e677cf1c00",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dosing_1\", \"treatmentName\": \"that delivers\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"Diabetes Mellitus\\nRationale:\\nNasal glucagon (LY900018) is a powder formulation of human glucagon for the rescue treatment of hypoglycemia \\npackaged in a user-friendly, single-use, nasal dosing device \"}, {\"id\": \"dosing_2\", \"treatmentName\": \"demonstrate that\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"ments to increase PG.  The nadir is defined as the minimum PG measurement at the time of \\nor within 10 minutes following glucagon administration.\\nObjectives/Endpoints:\\nObjectives\\nEndpoints\\nPrimary\\nTo \"}, {\"id\": \"dosing_3\", \"treatmentName\": \"non-inferior to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"s defined as the minimum PG measurement at the time of \\nor within 10 minutes following glucagon administration.\\nObjectives/Endpoints:\\nObjectives\\nEndpoints\\nPrimary\\nTo demonstrate that 3 mg LY900018 is \"}, {\"id\": \"dosing_4\", \"treatmentName\": \"tolerability of\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"minutes \\nafter administration of glucagon.  The nadir is defined \\nas the minimum PG value at the time of or within \\n10 minutes following glucagon administration.\\nSecondary\\n\\nTo compare the safety and \"}, {\"id\": \"dosing_5\", \"treatmentName\": \"LY900018 with\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"tration of glucagon.  The nadir is defined \\nas the minimum PG value at the time of or within \\n10 minutes following glucagon administration.\\nSecondary\\n\\nTo compare the safety and tolerability of 3 mg \\n\"}, {\"id\": \"dosing_6\", \"treatmentName\": \"profile of\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"he minimum PG value at the time of or within \\n10 minutes following glucagon administration.\\nSecondary\\n\\nTo compare the safety and tolerability of 3 mg \\nLY900018 with 1 mg IMG\\n\\nTo characterize the PK \"}, {\"id\": \"dosing_7\", \"treatmentName\": \"compared to\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \" time of or within \\n10 minutes following glucagon administration.\\nSecondary\\n\\nTo compare the safety and tolerability of 3 mg \\nLY900018 with 1 mg IMG\\n\\nTo characterize the PK profile of 3 mg LY900018 \\n\"}, {\"id\": \"dosing_8\", \"treatmentName\": \"to\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 250.0, \"unit\": \"mg\"}], \"durationDescription\": \"14 days\", \"sourceText\": \"\\n14 days\\nDay\\n-1\\nDay 1\\nWithin \\n282 days \\nafter last \\nstudy \\ntreatment\\nClinical Assessments\\nInformed Consent\\nX\\nRandomization\\nX\\nAdmission to CRU\\nX\\nX\\nAdmission can be \\nrescheduled if PG level is \\nnot 90 \"}, {\"id\": \"dosing_9\", \"treatmentName\": \"which delivers\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"iabetes treatments. LY900018 is a \\npowder formulation of synthetic human glucagon in a user-friendly, single-use, nasal dosing \\n\\n\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 20\\nLY900018\\ndevice \"}, {\"id\": \"dosing_10\", \"treatmentName\": \"efficacy between\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"leted in non-Japanese adults with T1DM \\nand T2DM:  Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study\\n(Study I8R-MC-B002 [B002]).  Studies IGBC and IGBA demonstrated comparable safety and \\n\"}, {\"id\": \"dosing_11\", \"treatmentName\": \"LY900018 and\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"adults with T1DM \\nand T2DM:  Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study\\n(Study I8R-MC-B002 [B002]).  Studies IGBC and IGBA demonstrated comparable safety and \\nefficacy between 3 mg \"}, {\"id\": \"dosing_12\", \"treatmentName\": \"effectiveness of\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"ctable glucagon in reversing insulin-induced \\nhypoglycemia in adult patients with T1DM only (Study IGBA) or patients with T2DM and \\nT1DM (IGBC).  Study B002 was an actual use study that evaluated the \"}, {\"id\": \"dosing_13\", \"treatmentName\": \"glucose around\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 50.0, \"unit\": \"mg\"}], \"sourceText\": \"this study.\\nThis study will expose patients to an insulin-induced hypoglycemia meant to simulate \\nhypoglycemia in a controlled setting.  The procedure of insulin-induced hypoglycemia targeting \\nnadir \"}, {\"id\": \"dosing_14\", \"treatmentName\": \"administered either\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}], \"sourceText\": \"erial blood sampling will be conducted to monitor bedside PG for safety.  \\nThe insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately \\n5 minutes later patients will be \"}, {\"id\": \"dosing_15\", \"treatmentName\": \"LY900018 or\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}], \"sourceText\": \" be conducted to monitor bedside PG for safety.  \\nThe insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately \\n5 minutes later patients will be administered either 3 mg \"}, {\"id\": \"dosing_16\", \"treatmentName\": \"assessment of\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"f the last visit or last scheduled procedure shown in the Schedule of \\nActivities (Section 2) for the last patient.\\n5.4.\\nScientific Rationale for Study Design\\nThis study design involves an open-label \"}, {\"id\": \"dosing_17\", \"treatmentName\": \"of approximately\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 50.0, \"unit\": \"mg\"}, {\"amount\": 20.0, \"unit\": \"mg\"}, {\"amount\": 60.0, \"unit\": \"mg\"}], \"sourceText\": \"n increase of 20 mg/dL from the PG nadir within 30 minutes \\nafter receiving glucagon, without the patient receiving additional actions to increase glucose.  It \\nis believed that an expected PG nadir \"}, {\"id\": \"dosing_18\", \"treatmentName\": \"infusion at\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 60.0, \"unit\": \"mg\"}, {\"amount\": 50.0, \"unit\": \"mg\"}], \"sourceText\": \"ng glucagon, without the patient receiving additional actions to increase glucose.  It \\nis believed that an expected PG nadir of approximately 50 mg/dL (approximately 5 minutes after \\nstop of insulin \"}, {\"id\": \"dosing_19\", \"treatmentName\": \"compare \\nagainst\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \" hypoglycemia\\nin Japan.\\nBased on LY900018 exposure, efficacy, and safety, the 3-mg dose was selected for the Phase 3 \\nstudies.  Therefore, in the current study, the 3-mg LY900018 dose will be used to \"}, {\"id\": \"dosing_20\", \"treatmentName\": \"have donated\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 400.0, \"unit\": \"ml\"}], \"durationDescription\": \"12 weeks\", \"sourceText\": \"igen\\n[30] show evidence of syphilis and/or are positive for syphilis test\\n[31] are women who are lactating\\n[32] use of daily systemic beta-blocker, indomethacin, warfarin, anticholinergic \\ndrugs\\n[33] \"}, {\"id\": \"dosing_21\", \"treatmentName\": \"months is\", \"frequency\": \"QW\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1200.0, \"unit\": \"ml\"}, {\"amount\": 400.0, \"unit\": \"ml\"}, {\"amount\": 800.0, \"unit\": \"ml\"}], \"durationDescription\": \"12 weeks\", \"sourceText\": \"400 mL or more blood in the last 12 weeks (males) or in the last \\n16 weeks (females), or any blood donation (including apheresis) within the \\nlast 4 weeks, or total volume of blood donation within 12 \"}, {\"id\": \"dosing_22\", \"treatmentName\": \"that exceeds\", \"frequency\": \"QW\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 21.0, \"unit\": \"units\"}, {\"amount\": 14.0, \"unit\": \"units\"}], \"durationDescription\": \"12 months\", \"sourceText\": \"f blood donation within 12 months is 1200 mL \\n(males)/800 mL (females) or more at screening\\n\\n\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 29\\nLY900018\\n[34] have an average weekly alcohol intake \"}, {\"id\": \"dosing_23\", \"treatmentName\": \"oz or\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 360.0, \"unit\": \"ml\"}, {\"amount\": 45.0, \"unit\": \"ml\"}, {\"amount\": 150.0, \"unit\": \"ml\"}], \"sourceText\": \"21 units per week (males \\nup to age 65) and 14 units per week (males over 65 and females), or are \\nunwilling to stop alcohol consumption from Day -2 to discharge from CRU in \\neach period (1 unit = 12 \"}, {\"id\": \"dosing_24\", \"treatmentName\": \"oz \\nor\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 45.0, \"unit\": \"ml\"}, {\"amount\": 360.0, \"unit\": \"ml\"}, {\"amount\": 150.0, \"unit\": \"ml\"}], \"sourceText\": \"ts per week (males over 65 and females), or are \\nunwilling to stop alcohol consumption from Day -2 to discharge from CRU in \\neach period (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 \"}, {\"id\": \"dosing_25\", \"treatmentName\": \"not exceed\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 21.0, \"unit\": \"units\"}, {\"amount\": 14.0, \"unit\": \"units\"}], \"sourceText\": \"Tobacco\\nPatients should refrain from caffeine-containing food/beverages (eg, cola, chocolate drinks, tea,\\nand coffee) from Day -1 to discharge from CRU in each period.  Patient alcohol intake should \\n\"}, {\"id\": \"dosing_26\", \"treatmentName\": \"comparison of\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"r participation in this study (screen failure) may not be \\nre-screened.\\n\\n\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 31\\nLY900018\\n7. Treatment\\n7.1.\\nTreatment Administered\\nThis study involves a \"}, {\"id\": \"dosing_27\", \"treatmentName\": \"nasally to\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"y not be \\nre-screened.\\n\\n\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 31\\nLY900018\\n7. Treatment\\n7.1.\\nTreatment Administered\\nThis study involves a comparison of 3 mg of LY900018 administered once \"}, {\"id\": \"dosing_28\", \"treatmentName\": \"Dosage Levels\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"g \\nglucagon administered IM (comparator).  Table IGBJ.2 shows the study treatment information.\\nTable IGBJ.2.\\nStudy Treatments\\nTreatment Name\\nLY900018\\nGlucaGen\\nDosage Formulation\\nDry powder\\nDry powder\\n\"}, {\"id\": \"dosing_29\", \"treatmentName\": \"glucagon\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}, {\"amount\": 3.0, \"unit\": \"mg\"}], \"sourceText\": \"tered IM (comparator).  Table IGBJ.2 shows the study treatment information.\\nTable IGBJ.2.\\nStudy Treatments\\nTreatment Name\\nLY900018\\nGlucaGen\\nDosage Formulation\\nDry powder\\nDry powder\\nDosage Levels\\n3 mg \"}, {\"id\": \"dosing_30\", \"treatmentName\": \"into\", \"frequency\": \"QD\", \"route\": \"IV\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 50.0, \"unit\": \"ml\"}], \"sourceText\": \"ection upon hypoglycemia onset\\nThe procedure for insulin-induced hypoglycemia will require an IV infusion of diluted human \\nregular insulin (0.3 U/mL by diluting 15 U human regular insulin [100 U/mL] \"}, {\"id\": \"dosing_31\", \"treatmentName\": \"maximum\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 2.0, \"unit\": \"g\"}, {\"amount\": 1.0, \"unit\": \"g\"}], \"sourceText\": \"), opiate medications (eg, morphine),\\nand medications with anti-emetic effects (eg, promethazine, prochlorperazine).\\nIn general, concomitant medication should be avoided; however, acetaminophen (1 g, \"}, {\"id\": \"dosing_32\", \"treatmentName\": \"either\", \"frequency\": \"QD\", \"route\": \"Intranasal\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 3.0, \"unit\": \"mg\"}, {\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"atory) and/or \\nglucagon (PK) measurements according to the Schedule of Activities (Section 2).\\n9.2.2. Glucagon Administration\\nApproximately 5 minutes after the insulin infusion has stopped, glucagon (\"}, {\"id\": \"dosing_33\", \"treatmentName\": \"Administration\\nGlucaGen\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \".  If a patient sneezes immediately after administration, document using \\nthe Nasal and Non-nasal Score Questionnaire (see Appendix 6 for a copy of the questionnaire).\\n9.2.2.2.\\nIntramuscular Glucagon \"}, {\"id\": \"dosing_34\", \"treatmentName\": \"The lyophilized\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"the Nasal and Non-nasal Score Questionnaire (see Appendix 6 for a copy of the questionnaire).\\n9.2.2.2.\\nIntramuscular Glucagon Administration\\nGlucaGen 1 mg for injection will be used as a comparator.  \"}, {\"id\": \"dosing_35\", \"treatmentName\": \"reconstituted with\", \"frequency\": \"QD\", \"route\": \"IM\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.1, \"unit\": \"ml\"}], \"sourceText\": \"aire (see Appendix 6 for a copy of the questionnaire).\\n9.2.2.2.\\nIntramuscular Glucagon Administration\\nGlucaGen 1 mg for injection will be used as a comparator.  The lyophilized 1 mg glucagon will \\nbe \"}, {\"id\": \"dosing_36\", \"treatmentName\": \"dose of\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"ramuscular Glucagon Administration\\nGlucaGen 1 mg for injection will be used as a comparator.  The lyophilized 1 mg glucagon will \\nbe reconstituted with 1.1 mL diluent according to the instruction.  A \"}, {\"id\": \"dosing_37\", \"treatmentName\": \"concentration of\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1.0, \"unit\": \"mg\"}], \"sourceText\": \"e lyophilized 1 mg glucagon will \\nbe reconstituted with 1.1 mL diluent according to the instruction.  A dose of 1 mg of glucagon in \\n\\n\\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 37\\nLY900018\\na \"}]"
              },
              {
                "id": "5ec69a50-8e7c-4b69-bb14-a38108bd6b0a",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"visit_1\", \"visitName\": \"screening\", \"targetDay\": -14, \"windowBefore\": 28, \"windowAfter\": 28, \"isRequired\": true, \"visitNumber\": 1, \"sourceText\": \"Patients will undergo a screening examination within 28 days prior to enrollment.  Patients will be administered a \\nsingle dose in Periods 1 and 2, which will be separated by a washout period of 3 to \"}, {\"id\": \"visit_7\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"Samples for immunogenicity, should be collected every 12 weeks (847 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of \\nthe baseline titer) or until 1 year a\"}, {\"id\": \"visit_2\", \"visitName\": \"Early Termination\", \"targetDay\": 1, \"windowBefore\": 3, \"windowAfter\": 14, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days.  Patients will return for \\na follow-up visit 26 to 30 days after the last study treatment.\\nNumber of Patien\"}, {\"id\": \"visit_3\", \"visitName\": \"Visit 26\", \"targetDay\": 1, \"windowBefore\": 26, \"windowAfter\": 30, \"isRequired\": true, \"visitNumber\": 4, \"sourceText\": \"a follow-up visit 26 to 30 days after the last study treatment.\\nNumber of Patients:\\nSeventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and \"}, {\"id\": \"visit_5\", \"visitName\": \"Day 1\", \"targetDay\": 1, \"windowBefore\": 3, \"windowAfter\": 14, \"isRequired\": true, \"visitNumber\": 5, \"sourceText\": \"Day 1\\n3 to\\n14 days\"}, {\"id\": \"visit_6\", \"visitName\": \"Randomization\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"Randomization\\nX\\nAdmission to CRU\"}, {\"id\": \"visit_8\", \"visitName\": \"Visit 1\", \"targetDay\": 1, \"windowBefore\": 1, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 7, \"sourceText\": \"dosing visit 1 to 7 days later.\\nFor safety monitoring during the hypoglycemia induction procedure, bedside PG levels will be \\nmeasured using the glucose analyzer no more than 10 minutes apart while PG\"}, {\"id\": \"visit_9\", \"visitName\": \"Eos\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 8, \"sourceText\": \"Eosinophils\\nAspartate aminotransferase (AST)\\nBasophils\"}, {\"id\": \"visit_4\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 26, \"windowAfter\": 30, \"isRequired\": true, \"visitNumber\": 9, \"sourceText\": \"a follow-up visit 26 to 30 days after the last study treatment.\\nNumber of Patients:\\nSeventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and \"}]"
              },
              {
                "id": "11a21b72-bcc4-4836-8d7b-d73b180bcd3e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"randomization_1\", \"ratio\": \"1:1\", \"method\": \"dynamic randomization\", \"centralRandomization\": true, \"sourceText\": \"I8R-JE-IGBJ(a) Clinical Pharmacology Protocol\\nPage 23\\nLY900018\\n5. Study Design\\n5.1.\\nOverall Design\\nThis is a Phase 3, multicenter, randomized, open-label, active comparator, single-dose, 2-period, \\n2-\"}"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "dde3b8aa-2a59-45db-ba29-e18c4a769dca",
            "text": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
            "type": {
              "id": "691dcab9-48b2-4aaf-843d-4aef44461aaa",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "055bffe5-1903-47ad-b3fe-b46c2204fbae",
            "text": "NCT03421379",
            "instanceType": "StudyIdentifier",
            "scopeId": "30b9bb70-d103-45bb-9841-5a9a61fa5874",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "e461c62f-2051-4a22-a201-f2b96d0a575d",
            "text": "I8R-JE-IGBJ",
            "instanceType": "StudyIdentifier",
            "scopeId": "30b9bb70-d103-45bb-9841-5a9a61fa5874",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "studyPhase": {
          "id": "0d65e2c7-fadd-4dbb-8520-4258e10cb17a",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "rationale": "Protocol version"
      }
    ],
    "organizations": [
      {
        "id": "651070c9-1102-4683-a96d-ecbb6ac8f786",
        "name": "Eli Lilly and Company",
        "type": {
          "id": "e67001ff-4167-43f6-ba2e-5a02f60146b4",
          "code": "Pharmaceutical Company",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "instanceType": "Organization"
      },
      {
        "id": "b27944f5-b271-4f31-9a5b-ad462eaa40f2",
        "name": "Eli Lilly Japan K.K",
        "type": {
          "id": "2b188ee2-11df-4dcb-961b-77cf9e436576",
          "code": "Pharmaceutical Company",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "instanceType": "Organization"
      }
    ],
    "indications": [
      {
        "id": "a41b99b4-7ce0-47e2-a2a0-7236f5fd2327",
        "name": "Insulin-induced Hypoglycemia",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus"
      }
    ],
    "name": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus"
  },
  "administrableProducts": [
    {
      "id": "d4f3e666-9769-46c1-8b28-07ed6d51ec14",
      "name": "LY900018",
      "instanceType": "AdministrableProduct",
      "doseForm": {
        "id": "b7c65c1f-359c-4d4e-a0f4-a1ea239e6653",
        "code": "Powder",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Powder",
        "instanceType": "Code"
      },
      "strength": "3 mg",
      "substanceIds": [
        "5cd64aa6-d4dd-44f5-8e26-f15dece909fe"
      ],
      "manufacturer": "Lilly"
    },
    {
      "id": "ab642a9a-c0c6-4642-ac4c-ee2932d72d82",
      "name": "GlucaGen",
      "instanceType": "AdministrableProduct",
      "doseForm": {
        "id": "83c9937a-ee78-428a-9601-482d3ac54dc2",
        "code": "Injection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Injection",
        "instanceType": "Code"
      },
      "strength": "1 mg",
      "substanceIds": [
        "db94fb5d-4a8f-4cb2-b7af-fa5e73625742"
      ],
      "manufacturer": "Novo Nordisk A/S"
    },
    {
      "id": "5997c1b9-1196-4a46-bbe8-b36d10494845",
      "name": "Human regular insulin",
      "instanceType": "AdministrableProduct",
      "doseForm": {
        "id": "3c7a4de4-632c-40cc-840a-41f9ecc42f81",
        "code": "Solution",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Solution",
        "instanceType": "Code"
      },
      "strength": "100 U/mL diluted to 0.3 U/mL",
      "substanceIds": [
        "e70ac8ff-805a-4707-b30e-a67c1873fe21"
      ]
    },
    {
      "id": "c7f38baf-1e35-41f3-9aef-8628f6988cc0",
      "name": "IV glucose",
      "instanceType": "AdministrableProduct",
      "doseForm": {
        "id": "d28f7d79-c37d-4857-a6a1-fb428893ed9c",
        "code": "Solution",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Solution",
        "instanceType": "Code"
      }
    }
  ],
  "administrations": [
    {
      "id": "9b37ef59-85b1-4cac-980a-35643aad670b",
      "name": "LY900018 3 mg single dose",
      "instanceType": "Administration",
      "dose": "3 mg",
      "doseFrequency": "single dose per period",
      "route": {
        "id": "0bdf9dcf-953a-446c-9023-47a2171df142",
        "code": "Intranasal",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intranasal",
        "instanceType": "Code"
      },
      "duration": "Single administration"
    },
    {
      "id": "e5c2b661-bdab-44c2-9e40-6bb21be8aa29",
      "name": "GlucaGen 1 mg single dose",
      "instanceType": "Administration",
      "dose": "1 mg",
      "doseFrequency": "single dose per period",
      "route": {
        "id": "ce783a33-84c3-4f9b-bfd3-073d2cc42b68",
        "code": "Intramuscular",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intramuscular",
        "instanceType": "Code"
      },
      "duration": "Single administration"
    },
    {
      "id": "9d22cd5a-3ef0-4989-8ed1-d52312872a68",
      "name": "Human regular insulin infusion",
      "instanceType": "Administration",
      "dose": "2 mU/kg/min, adjustable up to 3 mU/kg/min for T1DM or 4 mU/kg/min for T2DM",
      "doseFrequency": "once per period",
      "route": {
        "id": "ac885745-54b0-41f4-9971-096a121ead36",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until bedside plasma glucose level is <60 mg/dL, for a maximum of 4 hours."
    },
    {
      "id": "6f3e6cb6-7945-410c-b2da-8a9103977e00",
      "name": "IV glucose rescue",
      "instanceType": "Administration",
      "dose": "As deemed clinically necessary",
      "doseFrequency": "As needed",
      "route": {
        "id": "ef9498a0-7076-4a9c-9837-466d21ed0d9e",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "As needed"
    }
  ],
  "substances": [
    {
      "id": "5cd64aa6-d4dd-44f5-8e26-f15dece909fe",
      "name": "glucagon",
      "instanceType": "Substance",
      "description": "A synthetic single-chain, 29-amino-acid polypeptide identical to human glucagon."
    },
    {
      "id": "db94fb5d-4a8f-4cb2-b7af-fa5e73625742",
      "name": "human regular insulin",
      "instanceType": "Substance",
      "description": "Active substance used to induce hypoglycemia."
    },
    {
      "id": "e70ac8ff-805a-4707-b30e-a67c1873fe21",
      "name": "glucose",
      "instanceType": "Substance",
      "description": "Active substance in rescue medication for insufficient response to glucagon."
    }
  ],
  "narrativeContents": [
    {
      "id": "ed038bf7-9d86-41c6-b125-6b16423eab57",
      "name": "Protocol Synopsis",
      "order": 0,
      "instanceType": "NarrativeContent",
      "sectionNumber": "1",
      "sectionTitle": "Protocol Synopsis",
      "sectionType": {
        "id": "0894bbb3-6155-4612-a97e-4098d76adbe7",
        "code": "Synopsis",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Synopsis",
        "instanceType": "Code"
      }
    },
    {
      "id": "9f773553-aacb-418a-9dc8-614cb1d2e8c5",
      "name": "Schedule of Activities",
      "order": 1,
      "instanceType": "NarrativeContent",
      "sectionNumber": "2",
      "sectionTitle": "Schedule of Activities",
      "sectionType": {
        "id": "dc31b224-4ec1-483a-ba43-ebf133adfa0e",
        "code": "Study Procedures",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Study Procedures",
        "instanceType": "Code"
      }
    },
    {
      "id": "0d70383a-4b26-4ab5-a5f7-5ec6c295483d",
      "name": "Introduction",
      "order": 2,
      "instanceType": "NarrativeContent",
      "sectionNumber": "3",
      "sectionTitle": "Introduction",
      "sectionType": {
        "id": "69eeaf95-48ff-4c02-aa91-e49e61e98c5e",
        "code": "Introduction",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Introduction",
        "instanceType": "Code"
      },
      "childIds": [
        "28b5d4ba-a69a-4a50-9a8d-b389788e3b9e",
        "1ef1e219-a5c7-40a3-946a-eee406ec3a93",
        "41c874e4-fd16-45db-be72-8ed93ff9db8b"
      ]
    },
    {
      "id": "05060927-3702-4330-a7f0-7eae3210867b",
      "name": "Objectives and Endpoints",
      "order": 3,
      "instanceType": "NarrativeContent",
      "sectionNumber": "4",
      "sectionTitle": "Objectives and Endpoints",
      "sectionType": {
        "id": "1e7e0966-927c-4730-be75-9ed241db63be",
        "code": "Objectives",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Objectives",
        "instanceType": "Code"
      }
    },
    {
      "id": "50b9a29f-88ed-4180-849a-91da67b363a3",
      "name": "Study Design",
      "order": 4,
      "instanceType": "NarrativeContent",
      "sectionNumber": "5",
      "sectionTitle": "Study Design",
      "sectionType": {
        "id": "5ec572cc-592b-4788-b9d6-41dae943fd6c",
        "code": "Study Design",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Study Design",
        "instanceType": "Code"
      },
      "childIds": [
        "be3ca95c-973a-4c83-80b5-fdb7ae49a720",
        "168f70d1-e71e-4abe-ac09-df1879215950",
        "7e7a73b4-699e-4d7b-b4f7-dd5bec15a4e3",
        "3e90cebe-3cb5-4bf7-b1aa-6b0a74061847",
        "278493c8-fed8-4dfd-956b-691921146f39"
      ]
    },
    {
      "id": "ee4fcda2-93c4-43af-9cd8-ad7289413422",
      "name": "Study Population",
      "order": 5,
      "instanceType": "NarrativeContent",
      "sectionNumber": "6",
      "sectionTitle": "Study Population",
      "sectionType": {
        "id": "3cfd77f6-fc23-4ad5-bbef-acc5c82170cb",
        "code": "Study Population",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Study Population",
        "instanceType": "Code"
      },
      "childIds": [
        "b5a3ef88-9869-491a-8d82-d7b03aa6a071",
        "beac0101-b27a-4982-8d48-d463a1fdaa21",
        "fdbb521b-35b4-42d1-9f71-00e6342e6ec4",
        "1106f145-9ff6-49ca-ae9f-e2b7f4b01ce3"
      ]
    },
    {
      "id": "f8f20d2c-445a-4e5d-80af-850a1536650b",
      "name": "Treatment",
      "order": 6,
      "instanceType": "NarrativeContent",
      "sectionNumber": "7",
      "sectionTitle": "Treatment",
      "sectionType": {
        "id": "3c614960-1240-40e9-92df-1a97e82136c8",
        "code": "Treatment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Treatment",
        "instanceType": "Code"
      },
      "childIds": [
        "0656d4db-0e54-433a-bb1f-c1fbcefec307",
        "101f0870-78f9-4716-aa8a-576a15d10704"
      ]
    },
    {
      "id": "03eca88a-a5eb-4842-89a0-35fd00eb4ee1",
      "name": "Abbreviations and Definitions",
      "order": 7,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 1",
      "sectionTitle": "Abbreviations and Definitions",
      "sectionType": {
        "id": "84b5c06a-80a7-4716-9a34-02f61c16c276",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "cc81fe2b-f796-4125-a008-e1fa7c380868",
      "name": "Clinical Laboratory Tests",
      "order": 8,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 2",
      "sectionTitle": "Clinical Laboratory Tests",
      "sectionType": {
        "id": "611ecdf0-effa-48a6-bf32-c2a572b8374b",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "1afa1436-5117-42dd-a113-921410b8f1d4",
      "name": "Study Governance, Regulatory and Ethical Considerations",
      "order": 9,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 3",
      "sectionTitle": "Study Governance, Regulatory and Ethical Considerations",
      "sectionType": {
        "id": "d1f9d94b-e13f-47b4-9f33-aa9499133e02",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "6a6e741d-d546-4357-9031-812dc87caa19",
      "name": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
      "order": 10,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 4",
      "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
      "sectionType": {
        "id": "ef3aa069-bc2c-4a0a-b5a9-34b26b428aeb",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "ed8285eb-b8c6-4504-85b7-0088ef93a215",
      "name": "Blood Sampling Summary",
      "order": 11,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 5",
      "sectionTitle": "Blood Sampling Summary",
      "sectionType": {
        "id": "016aad8c-f55e-4754-83f8-708748c90cbe",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "2c33f6a8-7299-4ed3-9649-f89111932419",
      "name": "Nasal and Non-nasal Score Questionnaire",
      "order": 12,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 6",
      "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
      "sectionType": {
        "id": "62a27eba-e81a-4eec-8573-e50b918595df",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "e84c391e-7b87-4181-ae9a-167e18398eb1",
      "name": "Edinburgh Hypoglycemia Scale",
      "order": 13,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 7",
      "sectionTitle": "Edinburgh Hypoglycemia Scale",
      "sectionType": {
        "id": "62870f8c-a5f9-4157-950a-370c49aa06f9",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "0752b7fe-8c58-4692-8913-624725844c7f",
      "name": "Clarke Hypoglycemia Awareness Survey",
      "order": 14,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 8",
      "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
      "sectionType": {
        "id": "6cb2f1c7-e0ad-4814-a78c-776518129f89",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    },
    {
      "id": "5102cfe1-4d8c-43c0-9b1f-a7e863a86b5e",
      "name": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
      "order": 15,
      "instanceType": "NarrativeContent",
      "sectionNumber": "Appendix 9",
      "sectionTitle": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
      "sectionType": {
        "id": "90f4cbce-ac3e-49f7-a9ec-cbeea6851c65",
        "code": "Appendix",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Appendix",
        "instanceType": "Code"
      }
    }
  ],
  "abbreviations": [
    {
      "id": "deb73b6c-250b-4ec5-8cb6-b1ebf26930ad",
      "abbreviatedText": "IM",
      "expandedText": "intramuscular",
      "instanceType": "Abbreviation"
    },
    {
      "id": "c9afd6d9-84fc-4f59-900a-9468167c9979",
      "abbreviatedText": "IMG",
      "expandedText": "intramuscular glucagon",
      "instanceType": "Abbreviation"
    },
    {
      "id": "4a501703-7ebb-42bc-a57a-3242bd943838",
      "abbreviatedText": "T1DM",
      "expandedText": "type 1 diabetes mellitus",
      "instanceType": "Abbreviation"
    },
    {
      "id": "8f29a685-5b81-4f01-ae0a-38363398f01b",
      "abbreviatedText": "T2DM",
      "expandedText": "type 2 diabetes mellitus",
      "instanceType": "Abbreviation"
    },
    {
      "id": "f50774c7-ee38-4d57-ab88-b8922f6f343d",
      "abbreviatedText": "PG",
      "expandedText": "plasma glucose",
      "instanceType": "Abbreviation"
    },
    {
      "id": "98edad3b-4fdb-4bd7-9337-217e14cf40cc",
      "abbreviatedText": "AE",
      "expandedText": "adverse event",
      "instanceType": "Abbreviation"
    },
    {
      "id": "6bfc6d42-9e53-49ce-899c-2c111b358154",
      "abbreviatedText": "AUC",
      "expandedText": "area under the concentration versus time curve",
      "instanceType": "Abbreviation"
    },
    {
      "id": "73718899-5894-49e3-a5b1-e6734ca79d16",
      "abbreviatedText": "BGmax",
      "expandedText": "maximal plasma glucose concentration",
      "instanceType": "Abbreviation"
    },
    {
      "id": "c5298eb9-baca-4669-b9bd-4e1a579ff2c6",
      "abbreviatedText": "Cmax",
      "expandedText": "maximal concentration",
      "instanceType": "Abbreviation"
    },
    {
      "id": "d8392bcb-e625-4869-bc4d-2780e77e146b",
      "abbreviatedText": "PD",
      "expandedText": "pharmacodynamics",
      "instanceType": "Abbreviation"
    },
    {
      "id": "d37503fa-1f62-4bee-99e8-7167e3c9d52f",
      "abbreviatedText": "PK",
      "expandedText": "pharmacokinetics",
      "instanceType": "Abbreviation"
    },
    {
      "id": "6030186a-6bc4-49bc-883e-83f3681c38f3",
      "abbreviatedText": "SAE",
      "expandedText": "serious adverse event",
      "instanceType": "Abbreviation"
    },
    {
      "id": "44cdf0ef-020f-4202-9f1f-2a6df217bb79",
      "abbreviatedText": "TEAE",
      "expandedText": "treatment-emergent adverse event",
      "instanceType": "Abbreviation"
    },
    {
      "id": "8feb5066-c71b-4e74-a2e1-16c3cdc27698",
      "abbreviatedText": "Tmax",
      "expandedText": "time to maximal concentration",
      "instanceType": "Abbreviation"
    }
  ],
  "studyDefinitionDocument": {
    "id": "92636041-8a27-4f24-9a09-18e80e3c43e7",
    "name": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "I8R-JE-IGBJ(a)",
    "contentIds": [
      "ed038bf7-9d86-41c6-b125-6b16423eab57",
      "9f773553-aacb-418a-9dc8-614cb1d2e8c5",
      "0d70383a-4b26-4ab5-a5f7-5ec6c295483d",
      "05060927-3702-4330-a7f0-7eae3210867b",
      "50b9a29f-88ed-4180-849a-91da67b363a3",
      "ee4fcda2-93c4-43af-9cd8-ad7289413422",
      "f8f20d2c-445a-4e5d-80af-850a1536650b",
      "03eca88a-a5eb-4842-89a0-35fd00eb4ee1",
      "cc81fe2b-f796-4125-a008-e1fa7c380868",
      "1afa1436-5117-42dd-a113-921410b8f1d4",
      "6a6e741d-d546-4357-9031-812dc87caa19",
      "ed8285eb-b8c6-4504-85b7-0088ef93a215",
      "2c33f6a8-7299-4ed3-9649-f89111932419",
      "e84c391e-7b87-4181-ae9a-167e18398eb1",
      "0752b7fe-8c58-4692-8913-624725844c7f",
      "5102cfe1-4d8c-43c0-9b1f-a7e863a86b5e"
    ]
  },
  "studyAmendments": [
    {
      "id": "24ac466a-1896-434e-bbe1-24652147e68e",
      "number": "a",
      "scope": {
        "id": "0b69e2a7-1ecc-46dc-8fbf-65bc1e511811",
        "code": "Global",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Global",
        "instanceType": "Code"
      },
      "instanceType": "StudyAmendment",
      "summary": "The summary for Amendment (a) is referenced in Appendix 9, but the content of the appendix was not provided in the source document.",
      "effectiveDate": "2017-12-05",
      "previousVersion": "Original Protocol (2017-10-26)",
      "newVersion": "a"
    }
  ],
  "geographicScope": {
    "id": "2f8e2659-8acf-48e2-bd0c-5e53ceccbbcc",
    "name": "Study Geographic Scope",
    "scopeType": "Single Country",
    "instanceType": "GeographicScope",
    "countryIds": [
      "e923ed85-29d0-4ac4-97c8-996abc911122"
    ]
  },
  "countries": [
    {
      "id": "e923ed85-29d0-4ac4-97c8-996abc911122",
      "name": "Japan",
      "instanceType": "Country",
      "code": "JP"
    }
  ],
  "procedures": [
    {
      "id": "aaf88aff-9626-4182-98b4-302770aa425c",
      "name": "Venipuncture",
      "instanceType": "Procedure",
      "label": "Blood Draw",
      "description": "Collection of venous blood for laboratory analysis, including pharmacokinetics (PK), pharmacodynamics (PD), hematology, clinical chemistry, and serology.",
      "procedureType": {
        "id": "c93a5c2d-a256-4c8e-a407-d9f1f376c0d3",
        "code": "Sample Collection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Sample Collection",
        "instanceType": "Code"
      },
      "code": {
        "id": "3eb64997-cb80-4c6d-a762-a4d950911cdc",
        "code": "36415",
        "codeSystem": "CPT",
        "codeSystemVersion": "2024-09-27",
        "decode": "Collection of venous blood by venipuncture",
        "instanceType": "Code"
      }
    },
    {
      "id": "186894ee-1bdd-4186-9d64-bea610a7c50b",
      "name": "Urine Sample Collection",
      "instanceType": "Procedure",
      "label": "Urine Test",
      "description": "Collection of urine for urinalysis, pregnancy testing, and drug screening.",
      "procedureType": {
        "id": "b2f77606-da3e-4191-91e7-349d56252b04",
        "code": "Sample Collection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Sample Collection",
        "instanceType": "Code"
      }
    },
    {
      "id": "523248a5-fe87-4e64-b63a-3504251cbedb",
      "name": "Genetic Sample Collection",
      "instanceType": "Procedure",
      "label": "Genetic Sample",
      "description": "Collection of a single sample for pharmacogenetic analysis.",
      "procedureType": {
        "id": "55675616-18f9-4cfd-a552-f4b30df14c44",
        "code": "Sample Collection",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Sample Collection",
        "instanceType": "Code"
      }
    },
    {
      "id": "9a95fd62-3931-46eb-926f-78b1cb6a68b6",
      "name": "Insulin Infusion to Induce Hypoglycemia",
      "instanceType": "Procedure",
      "label": "Insulin Infusion",
      "description": "Intravenous (IV) insulin infusion to induce a controlled state of hypoglycemia.",
      "procedureType": {
        "id": "7b0b1428-ec8b-404b-8389-4592ff580280",
        "code": "Therapeutic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Therapeutic",
        "instanceType": "Code"
      }
    },
    {
      "id": "ed994354-19c1-4a09-97ba-d3fcf9290039",
      "name": "Nasal Glucagon Administration",
      "instanceType": "Procedure",
      "label": "Nasal Glucagon Admin",
      "description": "Administration of 3 mg LY900018 via a nasal dosing device.",
      "procedureType": {
        "id": "07ad5000-cf7a-4d6d-b143-8c1dc6ca30ad",
        "code": "Therapeutic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Therapeutic",
        "instanceType": "Code"
      }
    },
    {
      "id": "2a4ed5a2-d40c-40f8-91b2-24de02752db0",
      "name": "Intramuscular Glucagon Administration",
      "instanceType": "Procedure",
      "label": "IM Glucagon Admin",
      "description": "Administration of 1 mg intramuscular glucagon (IMG).",
      "procedureType": {
        "id": "9a6d6eb7-e3d5-4bf8-a6e0-da6f750e352d",
        "code": "Therapeutic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Therapeutic",
        "instanceType": "Code"
      }
    },
    {
      "id": "b618a6ad-f977-4574-8e20-b3f64706bb10",
      "name": "Intravenous Glucose Supplementation",
      "instanceType": "Procedure",
      "label": "IV Glucose Rescue",
      "description": "Administration of intravenous (IV) glucose as a rescue treatment for severe hypoglycemia if required.",
      "procedureType": {
        "id": "739ab866-bb41-4f2d-b5a3-d9826a6ce119",
        "code": "Therapeutic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Therapeutic",
        "instanceType": "Code"
      }
    },
    {
      "id": "179a2fdd-5a35-4658-b5f9-16914aefea0e",
      "name": "Vital Signs Measurement",
      "instanceType": "Procedure",
      "label": "Vital Signs",
      "description": "Measurement of supine blood pressure, pulse rate, and body temperature.",
      "procedureType": {
        "id": "8b3a7206-b877-4cb1-9fe6-161b95ccacf4",
        "code": "Monitoring",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Monitoring",
        "instanceType": "Code"
      }
    },
    {
      "id": "45dd2dab-83a4-47bb-8fd6-4f1d51d5e9ba",
      "name": "Bedside Plasma Glucose Monitoring",
      "instanceType": "Procedure",
      "label": "Bedside PG Monitoring",
      "description": "Frequent monitoring of plasma glucose levels using a bedside device during hypoglycemia induction and post-treatment for safety.",
      "procedureType": {
        "id": "f776cf60-9824-44d2-801b-b565fed91c7b",
        "code": "Monitoring",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Monitoring",
        "instanceType": "Code"
      }
    },
    {
      "id": "8ef9622d-c759-47f6-af90-11468415c588",
      "name": "Electrocardiogram",
      "instanceType": "Procedure",
      "label": "ECG",
      "description": "Recording of single and triplicate 12-lead ECGs to monitor cardiac activity.",
      "procedureType": {
        "id": "8229990c-d263-4415-8374-18eb4841d6e5",
        "code": "Diagnostic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic",
        "instanceType": "Code"
      }
    },
    {
      "id": "7e2c0964-579a-4a77-9d0c-5a6ff1607972",
      "name": "Physical Examination",
      "instanceType": "Procedure",
      "label": "Physical Exam",
      "description": "General physical examination performed at screening.",
      "procedureType": {
        "id": "b471f559-0cb0-48a0-b2bf-3464c4637a09",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    },
    {
      "id": "508bb197-818e-4ce7-8256-0caf797a779c",
      "name": "Height and Weight Measurement",
      "instanceType": "Procedure",
      "label": "Height/Weight",
      "description": "Measurement of patient height at screening and weight at specified timepoints.",
      "procedureType": {
        "id": "c310ca60-1e09-48c4-bffc-666c3638259c",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    },
    {
      "id": "d9556f5b-be5b-4b59-beee-765aa053ad86",
      "name": "Injection-Site Assessment",
      "instanceType": "Procedure",
      "label": "Injection Site Assessment",
      "description": "Assessment of the injection site for intramuscular glucagon (IMG) only.",
      "procedureType": {
        "id": "1d1b1c2f-126f-41a1-bd32-a3e3c722f8e7",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    },
    {
      "id": "7d04e0a7-3951-4130-8dd9-5aad31ff6b93",
      "name": "Nasal Inspection",
      "instanceType": "Procedure",
      "label": "Nasal Inspection",
      "description": "Inspection of the nasal passages before and after study treatment administration.",
      "procedureType": {
        "id": "ffb57e10-98b4-49f1-ae41-65378ee4b026",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    },
    {
      "id": "78ca6f06-4e5b-4d10-bbaa-e9914b4ca772",
      "name": "Edinburgh Hypoglycemia Scale",
      "instanceType": "Procedure",
      "label": "Hypoglycemia Questionnaire",
      "description": "Administration of a questionnaire to evaluate the recovery from clinical symptoms of hypoglycemia.",
      "procedureType": {
        "id": "9ab0d139-bf03-4637-9a1e-c0dfce91ea4d",
        "code": "Assessment",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Assessment",
        "instanceType": "Code"
      }
    },
    {
      "id": "15b95db8-89e2-4c56-b087-4368bfae1f9e",
      "name": "Laboratory Tests",
      "instanceType": "Procedure",
      "label": "Lab Tests",
      "description": "Includes Clinical Serology, Hematology, Clinical Chemistry, Urinalysis, HbA1c, Pregnancy Test, FSH, and Ethanol Testing.",
      "procedureType": {
        "id": "25e1a08f-7588-4b53-a16a-ae774626d260",
        "code": "Diagnostic",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic",
        "instanceType": "Code"
      }
    }
  ],
  "medicalDevices": [
    {
      "id": "478a0285-2cbe-4dae-a38a-7a28ada7e42d",
      "name": "Nasal Dosing Device",
      "instanceType": "MedicalDevice",
      "label": "Nasal Glucagon Device",
      "description": "A user-friendly, single-use, nasal dosing device that delivers 3 mg glucagon powder (LY900018).",
      "deviceType": {
        "id": "23d27aa9-3318-46ce-ac96-002ac5fb956b",
        "code": "Drug Delivery Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Drug Delivery Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "f74eb5f0-e3ad-4897-8cdb-d312f397aff8",
      "name": "Syringe and Needle",
      "instanceType": "MedicalDevice",
      "label": "IM Injection Kit",
      "description": "Device for intramuscular (IM) injection of reconstituted glucagon powder (GlucaGen).",
      "deviceType": {
        "id": "9be69629-279d-4f19-8c31-dcfb38bf46d9",
        "code": "Drug Delivery Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Drug Delivery Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "9aba6371-1e42-465b-a6cf-b6e0309ac73a",
      "name": "IV Infusion Setup",
      "instanceType": "MedicalDevice",
      "label": "IV Infusion",
      "description": "Equipment for administering intravenous (IV) insulin infusion to induce hypoglycemia.",
      "deviceType": {
        "id": "82bf95d0-1d1f-4675-8557-5b47ff17978c",
        "code": "Drug Delivery Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Drug Delivery Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "236ede24-403b-4760-bbb4-16399dc25ff1",
      "name": "Bedside Glucose Meter",
      "instanceType": "MedicalDevice",
      "label": "Glucose Meter",
      "description": "Device for bedside plasma glucose (PG) monitoring for safety.",
      "deviceType": {
        "id": "041d8db2-8d4c-4396-ad5b-c79edf568e0a",
        "code": "Monitoring Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Monitoring Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "9ab4159d-c237-4abd-868e-affae91a13f9",
      "name": "12-lead ECG Machine",
      "instanceType": "MedicalDevice",
      "label": "ECG Machine",
      "description": "Device for recording 12-lead electrocardiograms.",
      "deviceType": {
        "id": "3fcc1197-693d-4ab1-8916-2f43c2815557",
        "code": "Diagnostic Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Diagnostic Device",
        "instanceType": "Code"
      }
    },
    {
      "id": "20c3ab8f-ab42-469b-be07-c00e2ce5c128",
      "name": "Continuous Subcutaneous Insulin Infusion Pump",
      "instanceType": "MedicalDevice",
      "label": "CSII Pump",
      "description": "An insulin pump used by some patients for their daily insulin therapy.",
      "deviceType": {
        "id": "80da34e8-208c-49d5-afde-ebf4206303f8",
        "code": "Drug Delivery Device",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Drug Delivery Device",
        "instanceType": "Code"
      }
    }
  ],
  "ingredients": [
    {
      "id": "ab3ffa46-17ee-473e-9cc0-fed2bf47b2f9",
      "name": "Glucagon",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "13b01189-4544-4ff1-891e-730858427256"
    },
    {
      "id": "1bbb5f5b-167b-45c6-9dda-ec5b0c1bde1e",
      "name": "Insulin",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "feecf5f2-07b5-475a-a2b2-2c96d16ee1d5"
    },
    {
      "id": "4fb5d1ef-4345-4d36-83fe-d21ee9c23a4c",
      "name": "Glucose",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "97c72241-fe59-426f-b78f-ec7a0b6631d9"
    },
    {
      "id": "5858c517-25b5-412b-9344-ae002aab030f",
      "name": "Insulin Glargine",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "faa1a3a0-7f80-4354-84d2-f529e5a1efb0"
    },
    {
      "id": "bf264b2c-76da-4a14-adef-a6603cd93a98",
      "name": "Insulin Degludec",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "e599186f-4ce9-4940-b4d8-06f2954ec552"
    },
    {
      "id": "0f1f8957-0406-4c61-bcce-46b8a535acd9",
      "name": "Insulin Lispro",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "b328ba1c-cbc8-4c8c-a260-6e6dd522c7e7"
    },
    {
      "id": "f6dc1979-4fb1-4a81-a8ed-c8e13a30a7ec",
      "name": "Insulin Aspart",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "d2cd0b64-eae4-408a-b7a7-05764f11de3e"
    },
    {
      "id": "2393721b-99cf-4d32-b101-3ab5e50f633a",
      "name": "Insulin Glulisine",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "afc47852-a53c-46cf-b1ee-6734ce48c5bf"
    }
  ],
  "strengths": [
    {
      "id": "616426f3-818a-4f52-a746-e27708f7ad6f",
      "instanceType": "Strength",
      "value": 3,
      "unit": "mg"
    },
    {
      "id": "23d388ca-b072-41da-8366-d2e7d35e20bb",
      "instanceType": "Strength",
      "value": 1,
      "unit": "mg"
    },
    {
      "id": "42ed803f-5fed-4440-a76a-980045bffddf",
      "instanceType": "Strength",
      "value": 100,
      "unit": "U/mL",
      "numerator": {
        "value": 100,
        "unit": "U"
      },
      "denominator": {
        "value": 1,
        "unit": "mL"
      }
    },
    {
      "id": "3937ef5a-545e-4b8c-b45d-888e8e85597a",
      "instanceType": "Strength",
      "value": 300,
      "unit": "U/mL",
      "numerator": {
        "value": 300,
        "unit": "U"
      },
      "denominator": {
        "value": 1,
        "unit": "mL"
      }
    }
  ],
  "timings": [
    {
      "id": "c4febb80-ead8-4456-9d09-3efa197a8145",
      "name": "Screening Window",
      "type": "Within",
      "unit": "days",
      "instanceType": "Timing",
      "value": 28,
      "windowLower": -28,
      "windowUpper": -2
    },
    {
      "id": "0b419a10-b1d3-4715-b338-a6b777f4e323",
      "name": "Washout Period",
      "type": "Between",
      "unit": "days",
      "instanceType": "Timing",
      "value": [
        3,
        14
      ],
      "relativeTo": "Previous Visit",
      "windowLower": 3,
      "windowUpper": 14
    },
    {
      "id": "4e3199a5-b10a-425a-88cc-aad2fa5b3805",
      "name": "Follow-up Visit Window",
      "type": "At",
      "unit": "days",
      "instanceType": "Timing",
      "value": 28,
      "relativeTo": "Last Dose",
      "windowLower": -2,
      "windowUpper": 2
    },
    {
      "id": "4f023d0c-c650-48e4-b555-97cae4b68450",
      "name": "CRU Discharge",
      "type": "After",
      "unit": "hours",
      "instanceType": "Timing",
      "value": 6,
      "relativeTo": "Last Dose"
    },
    {
      "id": "0851934d-f68e-47e5-a21f-f6fcdd108a65",
      "name": "Study Drug Administration after Hypoglycemia",
      "type": "After",
      "unit": "minutes",
      "instanceType": "Timing",
      "value": 5
    },
    {
      "id": "257bbb4f-0c93-4e95-ae43-f1518c4ff39e",
      "name": "PK/PD Sampling Duration",
      "type": "Within",
      "unit": "hours",
      "instanceType": "Timing",
      "value": 4,
      "relativeTo": "Last Dose",
      "windowLower": 0,
      "windowUpper": 4
    },
    {
      "id": "8e35f8f8-a1f1-40dd-9c8b-fdc0e6495deb",
      "name": "Immunogenicity Follow-up Sampling",
      "type": "At",
      "unit": "days",
      "instanceType": "Timing",
      "value": 84,
      "relativeTo": "Previous Visit",
      "windowLower": -7,
      "windowUpper": 7
    }
  ],
  "conditions": [
    {
      "id": "ff1da6b5-8bf0-4363-bfc7-5107c1bc0aad",
      "name": "CRU Admission Rescheduling",
      "instanceType": "Condition",
      "description": "Condition for rescheduling admission to the CRU on Day 1.",
      "text": "Admission can be rescheduled if Plasma Glucose (PG) level is not 90 to 250 mg/dL on Day 1."
    },
    {
      "id": "d7ead3be-6f4d-42e2-b6d7-4f92daddc919",
      "name": "Stop Insulin Infusion",
      "instanceType": "Condition",
      "description": "Condition to stop the insulin infusion used to induce hypoglycemia.",
      "text": "Insulin infusion is stopped once bedside Plasma Glucose (PG) is <60 mg/dL."
    },
    {
      "id": "509f4979-1bba-41fa-bab4-47a9d0d7841f",
      "name": "Interim Safety Review",
      "instanceType": "Condition",
      "description": "A safety review is required after a subset of patients complete Period 2 before dosing the remaining patients.",
      "text": "Safety data will be reviewed after the first 6 patients are administered LY900018 in Period 2. The remaining patients will be dosed after confirmation of the safety."
    },
    {
      "id": "2e581673-c8fa-4cf3-8e1a-c705811f2292",
      "name": "Study Stopping Rule",
      "instanceType": "Condition",
      "description": "The entire study may be stopped based on the interim safety review.",
      "text": "Following the review of the safety data from the first 6 patients to complete Period 2 Day 1, the study will be stopped if deemed necessary for patient safety in the opinion of the Investigator and sponsor."
    },
    {
      "id": "bb76ff51-7f13-4392-8ebd-dfc5e3d13104",
      "name": "Additional Follow-up for TE ADA",
      "instanceType": "Condition",
      "description": "Condition triggering an extended follow-up period for immunogenicity testing.",
      "text": "Patients with treatment-emergent antidrug antibodies (TE ADA) at follow-up/ED will undergo additional follow-up."
    },
    {
      "id": "1bd5e2d2-3e04-4685-9d66-3521ece3e4bb",
      "name": "Patient Replacement Criteria",
      "instanceType": "Condition",
      "description": "Criteria for replacing a discontinued patient.",
      "text": "If patients discontinue from the study before completion of both periods with evaluable primary outcome for any reason, the patient may be replaced. Replacement should not occur beyond 75 patients enrolled."
    },
    {
      "id": "27369c28-f19b-455b-9084-4907cd1df17b",
      "name": "Inadvertent Enrollment",
      "instanceType": "Condition",
      "description": "Condition where a patient is found to not meet enrollment criteria after being enrolled.",
      "text": "The sponsor or investigator identifies a patient who did not meet enrollment criteria and was inadvertently enrolled."
    }
  ],
  "transitionRules": [
    {
      "id": "5937106a-3d45-437a-b20d-bf11319c8ae1",
      "name": "Screening to Treatment Period 1",
      "instanceType": "TransitionRule",
      "transitionType": "Epoch Transition",
      "fromElementId": "Screening",
      "toElementId": "Period 1",
      "text": "Patients who complete screening and meet all eligibility criteria will be randomized and proceed to Treatment Period 1."
    },
    {
      "id": "df0e974d-67c7-4437-86c3-b53334e224dd",
      "name": "Period 1 to Period 2",
      "instanceType": "TransitionRule",
      "transitionType": "Epoch Transition",
      "fromElementId": "Period 1",
      "toElementId": "Period 2",
      "text": "After completing Period 1, patients enter a washout period of 3 to 14 days before starting Period 2."
    },
    {
      "id": "af231d1b-18ba-49ce-9f6f-d6a4955646af",
      "name": "Discontinuation of Inadvertently Enrolled Patients",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "If an inadvertently enrolled patient is identified, a discussion must occur between the Lilly CP/CRP and the investigator to determine if the patient may continue. If both agree it is medically appropriate, documented approval must be obtained to allow the patient to continue."
    }
  ],
  "scheduleTimelineExits": [
    {
      "id": "c37a2537-ed40-40c9-8244-2adb24475286",
      "name": "Patient Decision",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "The patient, or legal representative, requests to be withdrawn from the study."
    },
    {
      "id": "f74e225c-7054-4c8c-ba4f-617542b8a765",
      "name": "Investigator Decision",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "The investigator decides that the patient should be discontinued from the study for any reason. If due to an AE/SAE, appropriate measures are to be taken."
    },
    {
      "id": "66367101-d295-4586-bf9f-c4c642f7cae3",
      "name": "Other Study Enrollment",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "Enrollment in any other clinical study involving an investigational product or other incompatible medical research."
    },
    {
      "id": "37976b2a-a77c-41c7-8060-f069083e9bdb",
      "name": "Medical, Safety, or Regulatory Reasons",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "Participation in the study needs to be stopped for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and good clinical practice."
    },
    {
      "id": "9e1aed91-e066-4c68-99da-91ffa0fdd83b",
      "name": "Lost to Follow-up",
      "exitType": "Early Termination",
      "instanceType": "ScheduleTimelineExit",
      "description": "A patient is considered lost to follow-up if they repeatedly fail to return for scheduled visits and cannot be contacted by the study site."
    },
    {
      "id": "2dfb2586-04fc-46bc-8407-a7d056aa45ad",
      "name": "Study Completion",
      "exitType": "Completion",
      "instanceType": "ScheduleTimelineExit",
      "description": "Patient completes both treatment periods and the final follow-up visit."
    }
  ],
  "analysisPopulations": [
    {
      "id": "47ad7d66-b2d6-4637-bf1e-4af1a1c7dba9",
      "name": "All Entered Set Population",
      "populationType": "Disposition",
      "instanceType": "AnalysisPopulation",
      "label": "AES",
      "description": "All patients who sign inform consent and enter in this study",
      "criteria": "Signed informed consent and entered the study"
    },
    {
      "id": "03be9be3-a177-4018-8f23-a0780fd558a5",
      "name": "All Randomized Set Population",
      "populationType": "Efficacy",
      "instanceType": "AnalysisPopulation",
      "label": "ARS",
      "description": "All patients who are randomized to study treatments",
      "criteria": "Randomized to study treatments"
    },
    {
      "id": "7e192dc0-d1ff-4340-a57c-54b6f1cea8f5",
      "name": "Full Analysis Set Population",
      "populationType": "Efficacy",
      "instanceType": "AnalysisPopulation",
      "label": "FAS",
      "description": "All randomized patients who receive at least 1 dose of study drug",
      "criteria": "Randomized and received at least 1 dose of study drug"
    },
    {
      "id": "75d0b87c-dbc5-4310-92cc-b6c87349f85d",
      "name": "Efficacy Analysis Set Population",
      "populationType": "Efficacy",
      "instanceType": "AnalysisPopulation",
      "label": "EAS",
      "description": "Patients in the FAS and have evaluable primary efficacy outcome",
      "criteria": "Member of FAS with an evaluable primary efficacy outcome"
    },
    {
      "id": "e13b9202-3f59-47eb-8c5e-79cdf1193f06",
      "name": "PK/PD Population",
      "populationType": "PK/PD",
      "instanceType": "AnalysisPopulation",
      "label": "PK/PD",
      "description": "Patients in the FAS and have evaluable PK/PD.",
      "criteria": "Member of FAS with evaluable PK/PD data"
    },
    {
      "id": "0d998338-868b-4cc2-b0d5-802f73a49017",
      "name": "Safety Analysis Set",
      "populationType": "Safety",
      "instanceType": "AnalysisPopulation",
      "label": "SAF",
      "description": "All randomized patients who receive at least 1 dose of study drug. All safety analyses will be conducted on data from the FAS.",
      "criteria": "Randomized and received at least 1 dose of study drug"
    }
  ],
  "characteristics": [
    {
      "id": "4670ad5b-96ed-427a-a69a-e4f66c2cc5d6",
      "name": "Age",
      "dataType": "Numeric",
      "instanceType": "Characteristic",
      "description": "Age of the subject at baseline"
    },
    {
      "id": "51fb1a61-9d49-4405-8c3a-f8cef8276d29",
      "name": "Sex",
      "dataType": "Categorical",
      "instanceType": "Characteristic",
      "description": "Sex of the subject"
    },
    {
      "id": "7e46e5ad-d09c-447b-b4e4-c46f82ead1ff",
      "name": "Race",
      "dataType": "Categorical",
      "instanceType": "Characteristic",
      "description": "Race of the subject"
    },
    {
      "id": "25944a6e-cb7f-4c8a-bc7a-d2a878b8a8ce",
      "name": "Ethnicity",
      "dataType": "Categorical",
      "instanceType": "Characteristic",
      "description": "Ethnicity of the subject"
    },
    {
      "id": "4256cc2e-d188-42a0-9b44-0bbb36a15ed1",
      "name": "Body weight",
      "dataType": "Numeric",
      "instanceType": "Characteristic",
      "description": "Body weight of the subject at baseline"
    },
    {
      "id": "ca2736e2-3ccf-46a4-999b-b5b6beacabe7",
      "name": "Height",
      "dataType": "Numeric",
      "instanceType": "Characteristic",
      "description": "Height of the subject at baseline"
    },
    {
      "id": "c1157f47-4535-4819-b965-046793df50fa",
      "name": "Body Mass Index",
      "dataType": "Numeric",
      "instanceType": "Characteristic",
      "description": "Body mass index of the subject at baseline"
    },
    {
      "id": "eb4c3963-42d7-4f89-98f7-f42b1de4d45a",
      "name": "Duration of diabetes",
      "dataType": "Numeric",
      "instanceType": "Characteristic",
      "description": "Duration of diabetes in years at baseline"
    },
    {
      "id": "751825f6-bb0d-434f-adb1-f8e75f4e4b94",
      "name": "Baseline HbA1c",
      "dataType": "Numeric",
      "instanceType": "Characteristic",
      "description": "Baseline HbA1c value (%)"
    },
    {
      "id": "387bb7bf-ce0a-438a-864d-ab2ceee6c17b",
      "name": "Baseline Clarke Hypoglycemia Awareness status",
      "dataType": "Categorical",
      "instanceType": "Characteristic",
      "description": "Baseline Clarke Hypoglycemia Awareness status (%)"
    },
    {
      "id": "78bb735a-044c-4570-af41-90584cea6129",
      "name": "Baseline substance use (alcohol)",
      "dataType": "Categorical",
      "instanceType": "Characteristic",
      "description": "Baseline substance use, specifically alcohol"
    },
    {
      "id": "a68b956c-4e16-420e-a458-20efe03f95bc",
      "name": "Previous diabetic therapy",
      "dataType": "Categorical",
      "instanceType": "Characteristic",
      "description": "Previous therapies for diabetes"
    },
    {
      "id": "6b893f83-422e-4070-9ce6-12ea0cffdc3d",
      "name": "Diabetes Type",
      "dataType": "Categorical",
      "instanceType": "Characteristic",
      "description": "Type of diabetes (Type 1 or Type 2)"
    }
  ],
  "documentContentReferences": [
    {
      "id": "ab4a2d8d-7f6d-4ed6-a727-1de820651c1d",
      "name": "Reference to Schedule of Activities",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "2",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference from Section 9, Study Assessments and Procedures, to Section 2 for the timing of study procedures."
    },
    {
      "id": "d7461c79-924f-4b27-90f2-d831371b62d0",
      "name": "Reference to Clinical Laboratory Tests Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 2",
      "sectionTitle": "Clinical Laboratory Tests",
      "description": "Reference from Section 9, Study Assessments and Procedures, to Appendix 2 for a list of laboratory tests."
    },
    {
      "id": "d0153060-4c20-4d21-a678-68af25528c59",
      "name": "Reference to Blood Sampling Summary Appendix",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 5",
      "sectionTitle": "Blood Sampling Summary",
      "description": "Reference from Section 9, Study Assessments and Procedures, to Appendix 5 for a summary of invasive samples."
    },
    {
      "id": "a769bea4-5224-4a51-b3ba-ac4ed7e64160",
      "name": "Reference to Edinburgh Hypoglycemia Scale",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 7",
      "sectionTitle": "Edinburgh Hypoglycemia Scale",
      "description": "Reference from Section 9.1.3, Exploratory Efficacy Assessments, to Appendix 7 for the self-reported assessment tool."
    },
    {
      "id": "3b485ffc-c949-4192-b959-2a2f98e17e94",
      "name": "Reference to Treatment Details",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7",
      "sectionTitle": "Treatment",
      "description": "Reference from Section 9.2.2, Glucagon Administration, to Section 7 for details regarding treatments."
    },
    {
      "id": "7478bc29-3a19-4b57-8c0e-79313238cb89",
      "name": "Reference to Nasal and Non-nasal Score Questionnaire",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 6",
      "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
      "description": "Reference from Section 9.2.2.1, Nasal LY900018 Administration, to Appendix 6 for the questionnaire to be used if a patient sneezes."
    },
    {
      "id": "0031f696-b4df-4ef6-b72d-a40f2eff8ff9",
      "name": "Reference to Hepatic Monitoring Tests",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 4",
      "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
      "description": "Reference from Section 9.5.5.2, Hepatic Safety, to Appendix 4 for the list of liver tests to be repeated in case of abnormalities."
    }
  ],
  "commentAnnotations": [
    {
      "id": "f48d1724-7878-4853-a638-8c33228f0130",
      "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Title Page",
      "pageNumber": 2
    },
    {
      "id": "95d8fcf2-09bb-4219-8cbc-02368714944b",
      "text": "At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Schedule of Activities",
      "pageNumber": 16
    },
    {
      "id": "2b0c1872-9214-457c-a3ad-e2890e4168e3",
      "text": "Pregnancy (maternal or paternal exposure to investigational product) does not meet the definition of an AE. However, to fulfill regulatory requirements any pregnancy should be reported following the SAE process to collect data on the outcome for both mother and fetus.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "9.3.1. Serious Adverse Events",
      "pageNumber": 40
    },
    {
      "id": "61107576-451f-4a6c-8e2d-487f37358141",
      "text": "Only severe hypoglycemic episodes will be reported separately as AEs. If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious in the CRF (that is, recorded as an SAE).",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "9.5.5.1. Hypoglycemic Event Reporting",
      "pageNumber": 44
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "9e86d0c2-0701-4b65-b580-82307027b2ca",
      "versionNumber": "I8R-JE-IGBJ(a)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2017-12-05",
      "description": "Protocol Amendment (a) to base protocol I8R-JE-IGBJ. Base protocol approved 26 October 2017.",
      "amendmentNumber": "Amendment (a)"
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "issues_found"
  }
}